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Abstract 
Structure-activity relationships for a series of 3-phenoxy-1,4-diarylazetidin-2-ones were 
investigated leading to the discovery of a number of potent antiproliferative compounds, 
including trans-4-(3-hydroxy-4-methoxyphenyl)-3-phenoxy-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (78b) and trans-4-(3-amino-4-methoxyphenyl)-3-phenoxy-
1-(3,4,5-trimethoxyphenyl)azetidin-2-one (90b). X-ray crystallography studies indicate the 
potential importance of the torsional angle between the 1-phenyl ‘A’ ring and 4-phenyl ‘B’ 
ring for potent antiproliferative activity, and that a trans configuration between the 3-
phenoxy and 4-phenyl rings is generally optimal. These compounds displayed IC50 values of 
38 nM and 19 nM respectively in MCF-7 breast cancer cells, inhibited the polymerization of 
isolated tubulin in vitro, disrupted the microtubular structure in MCF-7 cells as visualised by 
confocal microscopy, and caused G2/M arrest and apoptosis. Compound 90b possessed a 
mean GI50 value of 22 nM in the NCI60 cell line screen, displayed minimal cytotoxicity and 
was shown to interact at the colchicine-binding site on β-tubulin. Phosphate and amino acid 
prodrugs of both 78b and 90b were synthesised, of which the alanine amide 102b retained 
potency and is a promising candidate for further clinical development.  
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Introduction 
Tubulin polymerization plays a critical role in mitosis and cell division, and antimitotic drugs 
including vincristine, vinblastine, paclitaxel, docetaxel are one of the major classes of 
cytotoxic drugs in clinical use for treatment of cancers. The combretastatins are a group of 
diarylstilbenes isolated from the bark of the South African tree Combretum caffrum. 
Combretastatin A-4 (CA-4, 2, Figure 1) demonstrates potent cytotoxic activity against a 
range of human cancer cell lines e.g. leukaemia, ovarian and colon cancer including 
multidrug resistant (MDR) lines overexpressing P-glycoprotein (Pgp). It binds to the 
colchicine site of tubulin, inhibits tubulin polymerisation, and inhibits angiogenesis.1 A 
water-soluble, phosphate prodrug, combretastatin A-4 phosphate [CA-4P, 3, Figure 1 (also 
known as fosbretabulin disodium)], has been designated orphan drug status for the treatment 
of anaplastic thyroid cancer by both the FDA and the European Medicines Agency (EMA), 
and for the treatment of ovarian cancer by the FDA.2 The related amino acid amide 4 [(Figure 
1 (also known as AC7700 or AVE8026)] was recently investigated in phase III trials for 
treatment of advanced soft-tissue sarcomas but, in combination with cisplatin, it did not show 
a sufficient clinical benefit in patients to support its use as a therapeutic option.3 
Combretastatin A-1 diphosphate (also known as CA-1P) is under investigation for relapsed 
and refractory acute myelogenous leukemia, myelodysplastic syndromes and advanced solid 
tumors. Crolibulin [5, Figure 1 (also known as EPC2407 and crinobulin)] is another tubulin-
disrupting agent interacting at the colchicine-binding site and is in early phase I/II trials in 
combination with cisplatin focusing on anaplastic thyroid cancer.4 
The cis alkene configuration in 2 is essential for anti-cancer activity as it positions the 
aromatic rings at the optimal distance from each other and gives the optimal dihedral angle 
for interaction with the colchicine-binding site of tubulin (55° for 2 and 53° for 1).5-6 
Isomerization to the inactive trans configuration is observed on storage and in vivo 
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metabolism.7 To optimize potency and pharmacokinetic properties, many structural 
modifications of the combretastatin stilbene structure have been investigated, including the 
conformationally restricted analogues obtained by incorporating the 1,2-diarylalkene bridge 
into a carbocyclic or heterocyclic ring system. Heterocombretastatin derivatives have been 
synthesized based on, amongst others, five membered aromatic heterocyclic rings such as 
tetrazole, pyrazole, imidazole, triazole, isoxazole, thiazole and thiophene rings.8-10 Interest in 
small-molecule tubulin polymerization inhibitors continues unabated, with new analogues 
reported regularly (e.g. compound 6, Figure 1).11-13 
We have previously reported the antiproliferative activity of selective estrogen receptor 
modulator (SERM)-type compounds containing the azetidin-2-one (β-lactam) scaffold.14 
Previous research has indicated the potential of the azetidin-2-one ring as a template for 
antiproliferative agents, and we have demonstrated potent antiproliferative activity for series 
of 1,4-diarylazetidin-2-ones and trans-1,3,4-triarylazetidin-2-ones in human breast cancer 
cell lines.15-18 Our studies were furthered to design, synthesise and biologically evaluate a 
novel panel of compounds containing an aryloxy substituent at C-3 of the β-lactam ring. We 
wished to explore the role of the C-3 phenoxy substituent to determine if this flexible, 
electron-withdrawing substituent could provide potent antiproliferative compounds. 
Introduction of the phenoxy substitutent at C-3 also allowed us to examine the role of the 
cis/trans configuration of azetidin-2-ones on their antiproliferative effects. 
Chemistry and Stability Studies 
The preparation of the target azetidinones is illustrated in Schemes 1-8. The majority of 
compounds identified for synthesis contain a 3,4,5-trimethoxyaryl ring at N-1, present in ring 
A of 2, and an aryl ring with various substitution patterns at the C-4 position of the β-lactam 
ring (Ring B). Imines 14-39 were obtained by condensation of the appropriately substituted 
benzaldehydes and anilines in refluxing ethanol (Scheme 1). Nitrobenzaldehydes 7 and 8 
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were prepared by nitration of isovanillin at either the 2 or 6 position using concd nitric acid 
(Scheme 1). The reaction was optimised to produce both isomers in reasonable amounts (1:4 
of 7:8) by slow addition of the acid at room temperature. Nitrobenzaldehyde 11 was obtained 
in three steps (Scheme 1). Esterification of isovanillin to 9 was carried out to moderate the 
directing group effect of the hydroxy group. Ester 9 was nitrated with concd nitric acid, and 
the acetate group in 10 was cleaved with 5% sodium hydroxide to yield benzaldehyde 11 
(Scheme 1). Azidobenzaldehyde 13 was obtained in two steps; aminobenzyl alcohol was 
treated with sodium azide to afford alcohol 12, which yielded 13 upon oxidation with PCC 
(Scheme 1). Phenolic imines 31-39 were protected as tert-butyldimethylsiloxy (TBDMS) 
ethers (40-48, Scheme 1), which can be removed under mild conditions without degradation 
of the β-lactam ring. It is also feasible to firstly protect the phenolic benzaldehyde with the 
TBDMS group and then form the imine. 
 
The -lactam products 49-74 were obtained as racemic mixtures upon Staudinger reaction of 
the appropriate imine with phenoxyacetyl chloride in the presence of triethylamine (Scheme 
2). The cis isomer was isolated in all cases; the minor trans isomer was isolated for 
compounds 50, 55, 58 and 61 with cis/trans ratios determined as 1.5:1, 2:1, 1.5:1 and 2:1 
respectively, as indicated by J values of ~5 Hz (cis) and 1.5-2.2 Hz (trans) in the proton 
NMR spectra. Oxidation of the thioether 64 with m-CPBA resulted in the isolation of the 
sulfoxide 76, while the sulfone 77 was obtained when excess m-CPBA was used (Scheme 2). 
Introduction of the acrylate ester in compound 75 was achieved by olefinic coupling between 
bromo-substituted β-lactam 54 and ethyl acrylate with 1,3-
(diphenylphosphino)propane/palladium(II) acetate as catalyst. The 4-azidophenylazetidinone 
65 was prepared as a potential photoaffinity probe (Scheme 2).  
 
 6 
 
Deprotection of silylated β-lactams 66-74 with TBAF afforded phenolic products 78-86 
(Schemes 3 and 4). Reduction of the nitro group in compounds 61-63 and 84-86 was 
achieved by treatment with zinc dust in acetic acid for 7 days to yield the corresponding 
amines 87-92 in high yields (Scheme 4). To investigate the effect of introduction of the 3,4,5-
trimethoxyphenyl ring at the C-3 position of the β-lactam, 3,4,5-trimethoxyphenol was 
reacted with chloroacetic acid in the presence of sodium hydride to yield 93. Acid 93 was 
subsequently activated successfully with triphosgene in a one-pot Staundinger reaction with 
imine 40 to form 94. The silyl ether protecting group was removed using TBAF to give 
phenolic β-lactam 95 in 36% yield (Scheme 5). 
The effect of the reaction conditions on the stereochemical outcome of the Staudinger 
reaction was investigated. Many factors can affect the stereochemical outcome of the 
Staudinger reaction, including the nature of the ketene intermediate, the substitutents on the 
imine and the reaction conditions.19 The stereochemistry of 3-phenoxy β-lactams has been 
reported as differing depending on the reaction conditions.16, 20-22 -Lactam 78 was obtained 
by direct reaction of imine 40 and phenoxyacetic acid in dichloromethane using triphosgene 
as an acid-activating agent; only the cis isomer 78a was isolated (53% yield). β-Lactam 50 
was obtained using microwave irradiation (general method III.B), with a cis/trans ratio of 5:1 
in dichloromethane at 40 °C (yield 32%) and 10:1 in dichloroethane at 80 °C (yield 34%) 
compared with a cis/trans ratio of 1.5:1 with the conventional thermal method (yield 54%). In 
refluxing toluene, with a change in the order of addition of reagents, trans isomers 50a and 
61a were obtained as the major isomer (trans:cis ratios 7:1 and 5:1 respectively)(general 
method III.C). These results are in agreement with other studies where reaction conditions 
had a significant impact on the stereochemical outcome of the Staudinger reaction.16, 20-22 
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To examine the contribution of the azetidinone ring to the antiproliferative activity and 
stability of these compounds, reduction of 78a to azetidine 96 was achieved by treatment 
with diisobutylaluminium hydride. The IR spectrum of 96 indicated that the -lactam 
carbonyl absorption at 1739 cm-1 was no longer present. To our knowledge, this is the first 
report of the azetidine ring as a scaffold for CA4 analogues. The novel thione analogue 97 
was obtained on reaction of 78a with Lawesson’s reagent; the characteristic C=S absorption 
was observed at 1592 cm-1. 
Introduction of a cytotoxic alkylating functionality to CA-4 has been previously reported23 
and is potentially useful for the development of conjugates to overcome multidrug resistance. 
The phenolic (78a) and amino (90a) azetidinones were coupled with the alkylating cytotoxic 
drug chlorambucil using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI)/DMAP to 
give 98 and 99 respectively (Scheme 6). The cis and trans isomers of amino -lactam (90a 
and 90b) were coupled with the Fmoc-protected amino acids alanine and glycine to afford 
amides 100a, 100b and 101, which were deprotected using 1-octanethiol and TBAF to afford 
amines 102a, 102b and 103 (Scheme 7).24 Dibenzylphosphate esters 104a and 104b were 
obtained from phenolic azetidinones (78a and 78b) by treatment with dibenzylphosphite. 
Removal of the benzyl group is achieved by hydrogenation (Pd/C) to afford the phosphates 
105a and 105b respectively (Scheme 8).  
We have previously demonstrated stability of 3-phenyl and 3-thienyl -lactams over the pH 
range 4-9.18, 25 Preliminary stability studies of the 3-phenoxy -lactams 78b and 90b were 
carried out at acidic, neutral and basic conditions (pH 4, 7.4 and 9). The half-life (t½) was 
determined to be greater than 24 h at pH 7.4 for compound 90b. Half-lives were shorter at pH 
4 and 9 (18 h for both). Compound 78b was less stable than 90b at all pH values tested (t½ = 
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12, 8 and 11 h respectively at pH 4, 7.4 and 9). Based on this stability study, amino-
containing β-lactam 90b would be the most suitable for further development.  
Biological Results and Discussion 
Antiproliferative effects 
The -lactam products synthesized were screened for their antiproliferative activity in a cell 
viability assay with MCF-7 human breast cancer cell line using the MTT assay, with the 
results expressed as IC50 values (the drug concentration required to inhibit cell growth by 
50%)(Table 1). The β-lactams were also screened for their cytotoxicity using an LDH assay, 
with the results expressed as percentage cell death at a concentration of 10 μM (Table 1). 
Although the MTT assay alone cannot differentiate between growth inhibition and cytotoxic 
cell death, the LDH assay is specific for cell death, as it measures the concentration of the 
cytosolic protein lactate dehydrogenase (LDH), released upon cell lysis, in the supernatant. If 
a compound does not cause significant cell death, this suggests that it acts as a growth 
inhibitor. The -lactams examined in this study were designed to contain the 3,4,5-
trimethoxyphenyl substituent (Ring A) at the N-1 position of the -lactam ring as this was 
found to be optimal.18 The importance of the trimethoxyphenyl ring was reconfirmed by 
synthesis and evaluation of 83, which was over 100-fold less potent than compared to 78a 
(IC50 = 49 μM, 0.38 μM respectively) (Table 1). The majority of compounds prepared contain 
a phenoxy ring at position C-3 of the β-lactam. 
A number of methoxy-containing substituents located on the C-4 aryl ring were evaluated. 
Amongst the cis isomers, antiproliferative potencies decreased in the order of 52 > 49 > 50a 
> 51 (IC50 = 26, 29, 35, 171 μM respectively). For 50, with a 4-methoxyphenyl substituent at 
C-4, chromatographic separation of the cis and trans isomers facilitated the identification of 
the trans 50b product as having a superior IC50 value (IC50 = 6.9 M) compared with the cis 
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product 50a (IC50 = 35 M). Amongst the cis compounds with different substituents at the 4-
position of the C-4 aryl ring, SCH3-containing compound 64 displayed the most impressive 
potency (64 > 76 ≈ 65 > 57 ≈ 58a > 54 ≈ 79 > 77 ≈ 63 > 75 > 92; IC50 values 7.7, 20, 23, 31, 
31.6, 48, 48, 62, 63, 87, 160 μM respectively). A thiomethyl analogue of 2 with a 3-fold 
reduction in anti-tubulin activity and a 2-fold loss in potency compared to the corresponding 
4-methoxy analogue is known.26 Potent CA-4 analogues with a naphthalene ring have 
previously been reported,27 but in this series compounds 59 and 60 displayed poor activity 
with IC50 values in excess of 50 μM. The inclusion of the 3,4-methylenedioxyphenyl 
substitution pattern, present in steganacin and podophyllotoxin, also led to reduced potency 
for compound 53 (IC50 = 48 M). 
β-Lactam analogues containing 3,4-substitution patterns on the C-4 aryl ring were next 
examined. Amongst the cis-orientated analogues, the potency decreases in the order 78a > 81 
≈ 55a > 56 > 90a > 80 > 61a (IC50 values of 0.38, 4.5, 5.1, 6.3, 12.2, 32, 69 μM respectively, 
Table 1). Compound 78a has a B-ring substitution pattern identical to 2 and is the most 
potent of this mini-series, with a submicromolar IC50 value (0.38 μM). Both halogen-
containing compounds 55a and 56 displayed low micromolar activity (IC50=5.1, 6.3 μM). 
The fluorine group in 56 has the potential advantage of blocking Phase I metabolism 
mediated by CYP450. The cis bromo isomer 55a was 6-fold more potent than trans isomer 
55b (IC50 = 5.1, 31 μM respectively). Reduction of the nitro (61) to the amino group (90) 
leads to a large increase in potency for both the cis and trans isomers (2.5-fold and 26-fold 
respectively). Compound 90b was also highly potent in MDA-MB-321 breast cancer cells 
(IC50 = 0.015 M). 
Further investigations into the role of the aromatic hydroxyl and amino groups at C-4 were 
carried out to explore the requirements for activity. Firstly, compounds 82 and 91 were 
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synthesized, lacking the 4-methoxy group. Compound 82 displayed a considerable loss in 
potency compared to 78a (IC50 = 54 and 0.38 μM), while 90a was slightly more potent than 
91 (IC50 = 12.2 and 17 μM) (Table 1). In combination with the results above, this indicates 
that having both the hydroxyl and the methoxy groups in their respective positions on ring 
“B” is neccessay for activity of these β-lactam compounds. Three compounds with methoxy 
(50a), hydroxyl (79; 3:1 cis:trans) and amino (92) substitutents at the 4-position of the C-4 
aryl ring were evaluated, and their relative antiproliferative potencies confirm the 4-methoxy 
group as optimal (IC50 = 35, 48, 160 μM respectively). 
An interesting series of CA-4 analogues, retaining the 3-hydroxy, 4-methoxy substitution 
pattern but additionally including an amino group substituted at the remaining free positions 
of the C-4 aryl ring have been reported.28 A series of similarly substituted cis β-lactams were 
synthesized and evaluated (87, 88, 89 and their nitro precursors 84, 85 and 86). As noted 
above for cis and trans isomers of compounds 61 and 90, reduction of the nitro to the amino 
yields compounds with increased potency. Compounds 87, 88 and 89 were only obtained as 
the cis isomer, and in comparison to 90a they all display increased potency (IC50 = 18.5, 20, 
8.8 and 27 μM respectively). It is possible that the trans isomers of these compounds may be 
even more potent.  
A number of clinical trials of CA-4P in combination with an established chemotherapeutics 
are in progress.4 Compounds 78a and 90a were successfully coupled to chlorambucil via 
ester and amide linkages respectively to yield 98 and 99 respectively. Ester compound 98 had 
an equipotent antiproliferative effect when compared to 78a, and much greater than the 
reported IC50 value for chlorambucil in MCF-7 cells (97 μM).29 There was a marked increase 
in cell death from 2.8% to 8% compared to 78a, most likely due to the toxic effects of 
chlorambucil. In contrast, amide 99 showed a huge loss in antiproliferative potency (IC50 = 
145μM). One explanation for these observations was that the ester linkage of 98 was cleaved 
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in situ by cellular esterases, whilst amide 99 would not be subject to this effect, would remain 
intact and hence would be unable to inhibit the polymerization of tubulin. 
Phosphate esters 105a and 105b were prepared to improve water solubility, and demonstrated 
reduced antiproliferative effects (IC50 = 42 and 23 μM respectively) when compared with the 
corresponding phenols 78a and 78b (Table 1). It is likely that rapid in vivo dephosphorylation 
would occur for 105a and 105b, analogous to that reported for CA-4P.30 Interestingly, amino 
acid prodrugs 102a and 103 displayed improved potency compared to the parent amine 90a, 
while trans amide 102b demonstrates submicromolar antiproliferative activity (IC50 = 0.23 
M). These amides are expected to be hydrolysed to the active amine in vivo due to the 
widespread presence of aminopeptidases in blood, in a similar manner to that reported for the 
CA-4 type compound 4.31 
Previous research has demonstrated that an intact β-lactam ring is required for potent 
antiproliferative activity.18 A major question arising from these findings concerns the role of 
the β-lactam ring itself, particularly the role of the carbonyl group at C-2. A major 
degradation pathway for the β-lactam ring in penicillins and monobactams is hydrolysis. If 
the C-2 of the ring proved amenable to modification without affecting biochemical activity it 
may provide access to a series of compounds that would show increased stability in vivo. 
Transformation of the carbonyl to a thione (97) and reduction to an azetidine (96) were 
investigated. However large decreases in potency were observed for both compounds 97 and 
96 compared to 78a (Table 1; IC50 values 7.5, 3.3 and 0.38 μM respectively). Compound 96 
also induced a large increase in cell death to nearly 20% (compared to 2.8% for 78a). This 
indicates that the carbonyl group at C-2 is crucial to antiproliferative effects of these β-
lactams.  
Further Antiproliferative Screening and In Vivo Studies 
 12 
 
Following a review of the initial antiproliferative data obtained, compounds 78a and 90b 
were selected as representative examples for evalution in the National Cancer Institute’s 
Division of Cancer Treatment and Diagnosis (DCTD) Development Therapeutics Program 
(DTP).32 Analysis of their drug-like (Lipinski) properties from a Tier-1 profiling screen, 
together with predictions of permeability, metabolic stability, blood brain barrier partition, 
plasma protein binding and human intestinal absorption properties, indicated that they are 
moderately lipophilic-hydrophilic drugs and are suitable candidates for further investigation 
(Tables S1 and S2, Supporting Information). 
In the initial NCI one-dose (10 μM) cell line screen, compounds 78a and 90b displayed 
promising activity, particularly against leukemia and colon cancer cell lines. Subsequent five-
dose screening to evaluate GI50 (50% growth inhibition) and LC50 (50% lethal concentration) 
was carried out in NCI panel of 56 cell lines using the sulphorhodamine B (SRB) protein 
assay (Table S3, Supporting information). The GI50 measures the growth inhibitory power of 
the test agent, while the LC50 value signifies a cytotoxic effect. For phenolic compound 78a, 
the GI50 values were in the submicromolar range for 29 of the panel cell lines investigated, 
including all of the leukemia and prostate cancer cell lines, four renal cancer lines and five 
melanoma lines. The mean GI50 value across all cell lines tested was 1.45 μM. Particularly of 
interest was the activity of the compound against MCF-7 (GI50 = 0.36 μM) which is in close 
agreement with the IC50 value of 0.38 μM determined in-house. The significant activity of 
amino compound 90b displayed in the one-dose screen translated into excellent broad-
spectrum antiproliferative activity in the five-dose assay with GI50 values below 10 nM in all 
but four of the panel cell lines tested. It was active against all of the leukemia, prostate and 
renal cancer cell lines tested indicating the potential of this compound for a wide range of 
therapeutic applications. The activity of the compound against MCF-7 (GI50 <10 nM) is in 
agreement with the IC50 value of 13 nM determined in-house. The mean GI50 value for 
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compound 90b across all cell lines in the panel is 22.4 nM (Table S3, Supporting 
information). 
Cytotoxicity (determined as the LC50 value) was determined to be greater than 100 M in all 
but 5 cell lines (compound 78a), and in all but 4 cell lines (compound 90b), indicating 
minimal toxicity (Table S3, Supporting information). This supports the results of our in-
house cytotoxicity results, where 78a caused only 2.8% cell death (at 10 μM) and 90b 
resulted in 10.2% cell death (Table 1). Based on the excellent in vitro results for compound 
90b, it was progressed to in vivo studies performed by the NCI with 12 cancer types using the 
hollow fibre assay.33 The maximum tolerated dose (MTD) for 90b in athymic nude mice was 
determined to be 100 mg/kg/dose (IP), and from this the high dose for the hollow fibre assay 
was calculated to be 37.5 mg/kg/dose [=(MTD×1.5)/4]. A positive result (50% or greater 
reduction in net percent cell growth) was found for one cancer type when injected 
subcutanteously (UACC-62 melanoma). 
The NCI matrix COMPARE analysis,34 which measures the correlation between two 
compounds with respect to their differential antiproliferative activity, demonstrated good 
correlation between 78a, 90b and CA-4 (r = 0.53 and 0.63 respectively; r = correlation 
coefficient). The COMPARE algorithm was also used to compare the differential 
antiproliferative activities of 90b to compounds with known mechanisms of action in the NCI 
Standard Agent Database and it showed the highest correlations to tubulin-targeting agents 
including maytansine [an analogue of which, in conjugation with trastuzumab (T-DM1), has 
been recently approved by the FDA for late-stage, HER-2 positive breast35], rhizoxin and the 
clinically-used vinca alkaloids vincristine sulfate and vinblastine sulfate (Table S4, 
Supporting information). 
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Effects of β-Lactams on Tubulin Polymerisation, Microtubule Struture in MCF-7 Cells 
and Bisthioalkylation of β-Tubulin by EBI 
Due to the results of the COMPARE analysis, and the structural similarity of these 
compounds to previously reported tubulin-targeting agents, the effects of selected β-lactams 
on both tubulin polymerization and the microtubular structure of MCF-7 cells were 
investigated. A number of the CA-4 -lactam analogues (compounds 57, 58b, 78a, 78b and 
90b) were evaluated for their ability to inhibit the assembly of isolated, purified bovine 
tubulin. The effect of the test compounds on tubulin polymerization was determined by 
recording the absorbance at 340 nm over time, as light is scattered by microtubules to an 
extent that is proportional to the concentration of microtubule polymer. Vmax values (maximal 
rate of polymerization) were calculated for each compound as the Vmax value gives a sensitive 
indication of tubulin/ligand interactions. The fold changes in the Vmax values for the inhibition 
of tubulin polymerization with reference to the vehicle control were calculated for each 
compound (Table 2). Compounds 78a, 78b and 90b were shown to inhibit the polymerization 
of tubulin at 10 M; 78b was the most potent with a reduction in the Vmax value of 3.2 fold 
when compared with 2 which demonstrated a 6-fold reduction in the rate of tubulin 
polymerization. A 1.6-fold reduction in the Vmax for tubulin polymerization was observed for 
compound 90b, while a 1.1-fold reduction was observed for the less potent cis isomer 78a. 
Compounds 57 and 58b did not cause any change in the Vmax value compared to vehicle 
control, indicating that they do not inhibit the polymerization of tubulin and explaining their 
poor antiproliferative activity in MCF-7 cells.  
Subsequently, we investigated alterations induced by β-lactam 90b on the microtubule 
network of MCF-7 cells by confocal microscopy. Confocal analysis of MCF-7 cells stained 
with α-tubulin mAb demonstrated a well organised microtubular network in cells treated with 
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vehicle control (Figure 2) and in untreated cells (data not shown). Exposure to the 
microtubule-stabilising agent paclitaxel induced the formation of microtubule bundles and 
pseudo asters (Figure 2).36 Cells exposed to 2 or β-lactam 90b for 16 h were characterised by 
complete loss of microtubule formation consistent with depolymerised microtubules (Figure 
2). Additionally, cells treated with 2 or β-lactam 90b contained multiple micronuclei, a 
phenomenon described as mitotic catastrophe.37 The findings are in agreement with previous 
reports that 2 induced mitotic catastrophe in non-small cell lung cancer cells,38-39 human 
endothelial cells (HUVEC),40 human lung carcinoma cells (H460)40 and human breast cancer 
cells (MCF-7).41 Taken in conjuction with the effects on polymerization of isolated tubulin, 
the confocal imaging results confirm that β-lactam 90b is targeting tubulin. 
Due to the structural similarities between our compounds, 2, and many other analogues of 
CA-4, we carried out a whole-cell based assay to characterize the binding-site of these 
compounds on tubulin. N,N’-ethylene-bis(iodoacetamide)(EBI) is an alkylating agent that 
crosslinks cysteine residues at positions 239 and 354 in the colchicine-binding site of tubulin, 
forming a β-tubulin-EBI adduct. This adduct is detectable by Western blotting as an 
immunoreactive band that migrates faster than β-tubulin. Cells that are pretreated with a 
colchicine-site inhibitor, such as 1 and 2, prevent the formation of the β-tubulin-EBI 
adduct.42-43 MCF-7 cells were treated with a selected β-lactam 90b (10 μM) for 2 h followed 
by EBI for an additional 1.5 h (Figure 3). Control samples show the presence of the β-
tubulin-EBI adduct at a lower position, indicating that EBI has crosslinked Cys239 and 
Cys354 on β-tubulin. Adduct formation is inhibited in cells treated with β-lactam 90b, 
indicating that 90b is binding at the colchicine-site of tubulin. 
Cell Cycle Analysis by Flow Cytometry 
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Further biochemical investigations were carried out to investigate the effects of compounds 
78b and 90b on the cell cycle distribution of MCF-7 breast cancer cells after 24, 48 and 72 hr 
of treatment. Cell cycle analysis was carried out by staining cells with propidium iodide and 
analyzing their DNA content by flow cytometry. A statistically significant increase in the 
percentage of cells in the G2/M phase after both 24 and 48 hr was noted for compound 90b 
(57% and 73% respectively) compared to the vehicle control (25% and 26%)(Figure 4), 
indicating mitotic blockade. After 72 hr, there was a significant increase in the percentage of 
apoptoic cells, as indicated by the sub-G0G1 peak, for both compounds 78b and 90b 
compared to the vehicle control (34%, 35% and 4% respectively)(Figure 4). The cell cycle 
analysis results for 90b are typical of tubulin-targeting compounds, which characteristically 
cause G2/M arrest followed by apoptosis.
44  
X-Ray Structural Study 
An X-ray crystallography study of eight of the -lactam products was undertaken to confirm 
the cis/trans stereochemical assignments and explore possible important structural features 
for potent activity. ORTEP diagrams for trans compounds 78b and 90b are presented in 
Figure 5, and diagrams for cis compounds 49, 60, 77 and 55a and trans compounds 50b and 
58b are shown in Figure S1 (Supporting Information).  
Generally, a trans arrangement between C-3 and C-4 of the β-lactam ring was found to confer 
superior antiproliferative activity compared to the corresponding cis compound (Table 1). 
The X-ray structures determined demonstrated a conformation for the azetidinones where the 
rings A and B (i.e. aromatic rings located at N-1 and C-4 of the -lactam ring) are not 
coplanar. The -lactam ring forms a rigid scaffold which accommodates the planar 
hydrophobic aryl rings A and B, required for interaction with the colchicine binding site of 
tubulin. The torsional angles (Ring A/B) observed for cis compounds 49, 55a, 60 and 77 were 
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calculated to be 70.9°, 56.3°, -75.0° (-62.8°) and 72.0° respectively, while the corresponding 
values for the trans compounds 50b, 58b, 78b and 90b were 56.3°, 56.2° (-54.2°), 60.2°, and 
-62.1° respectively (Table S5, Supporting Information; numbers in parentheses refer to the 
second crystallographically independent molecule in the asymmetric unit). The Ring A/B 
torsional angle in most cases was found to be greater for the cis compounds than for the trans 
compounds. The exception is compound 55a, which interestingly was more potent in 
antiproliferative assays than the corresponding trans isomer 55b. The torsional angle for the 
most potent compounds 90a and 78a at -62.1°, 60.2° compares with the torsional angle (Ring 
A/B) determined for 1 and 2 of 55° and 53° respectively. As expected, the Ring B/C torsional 
angles were low for the cis compounds 49, 55a, 60 and 77 (10.8°, -1.6°, 0.4° (-7.4°) and -
6.1°) while the Ring B/C torsional angles for the trans compounds 50b, 58b, 78b and 90b 
and were determined to be -122.91°, 120.5° (124.7°), -122.9° and 128.5° (Table S5, 
Supporting Information; numbers in parentheses refer to the second crystallographically 
independent molecule in the asymmetric unit). This result indicates that a trans arrangement 
of rings B and C generally facilitates a more favourable interaction of rings A and B with the 
residues of the tubulin binding site. It also highlights the potential importance of the ring 
A/B torsional angle, where compounds with values greater than 70° possess poor 
antiproliferative activity. It should be noted that the unbound X-ray crystallographic structure 
may not be the bioactive conformation in vivo. 
Molecular modelling in the colchicine-binding site of tubulin 
Tubulin is a heterodimer of α and β subunits, with the colchicine site buried mostly in the β-
subunit but with some interactions with the α-subunit. Binding of DAMA-colchicine leads to 
the α-subunit of tubulin being unable to adopt its favoured straight conformation with β-
tubulin. It does this by steric interference with residues 101 and 181 in α-tubulin., forcing the 
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T7 loop and H8 helix to clash with the α-tubulin, and forcing the Lys β352 side chain to 
interfere with the α-tubulin. Two important residues (Val β318 and Cys β241) in the site have 
been identified from biochemical data. Modification of the Val β318 residue has been shown 
to reduce the sensitivity of tubulin to colchicine.45 Colchicine derivatives with groups 
substituted at the methoxy positions can crosslink with Cys β241.46 
The 3-bromo-4-methoxy compounds (55a and 55b) displayed reasonable activity in the low 
micromolar range, with cis isomer 55a displaying better antiproliferative activity than trans 
isomer 55b (IC50 = 5.1 μM and 31 μM respectively). By examining the ligand interactions for 
the docked compounds it becomes apparent that 55a maintains the important interactions 
with Cys β241 (polar), Val β318 (polar), Lys β352 (basic), and Val α181 (hydrophobic). The 
trans compound 55b does not maintain the interaction with Val β318 (Figure S2, Supporting 
Information). This may account for the fall in antiproliferative activity observed for 55b. 
The most potent compounds, phenolic 78b and amino 90b, displayed submicromolar activity. 
The trans isomer was favoured in both cases, in contrast to the observation for 55a and 55b, 
although this may be explained by their ring A/B torsional angles as described above. For 
compound 78, IC50 values of 0.38 μM and 0.038 μM were obtained for the cis and trans 
isomers respectively. Both isomers interact as expected with the residues reported by 
Ravelli,6 but there are small differences in the poses adopted by both isomers in the 
colchicine site (Figure 6). In the trimethoxy region of the two isomers, 78b more closely 
resembles the trimethoxy area of colchicine (78b is offset from DAMA-colchicine by 1.25 Å 
compared to 2.13 Å for 78a). In a similar manner, the methoxy group of the C-4 ring of 78b 
is placed 1.11 Å from that of DAMA-colchicine compared to 1.49 Å for 78a. It has been 
noted that, for many CA-4 analogues, the p-methoxy group of the B ring is essential for 
activity and the docked solution presented here indicates that the p-methoxy group plays a 
role in sterically interacting with the Lys β352. For the amino compounds (90a and 90b), cis 
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90a is considerably less potent than phenolic 78a whilst the trans isomer, 90b, is more active 
than 78b. The docked solution for the 90b shows that it maintains the same important 
contacts as 78b, but adopts a slightly different pose in the colchicine site. The trimethoxy 
region is offset by an average of 1.4 Å compared to 1.25 Å for the hydroxy compound (less 
than the offset of 2.13 Å for 78a). Finally, molecular docking for azetidine 96 (IC50=7.45μM) 
and thione 97 (IC50=3.3μM), both of which lack the β-lactam carbonyl group, shows that both 
compounds are no longer interacting with Val β318. From the previous examples the β-
lactam carbonyl appears to interact with three residues – Ala β250 (hydrophobic), Leu β255 
(hydrophobic), and Leu β248 (hydrophobic) which are members of the T7 loop H8 helix. It 
may be important for a ligand to interact in this way, since colchicine also interacts with these 
residues causing the T7 loop and H8 helix to move and interfere with α-tubulin. Removal of 
the carbonyl group may adversely affect biochemical activity by reducing these interactions. 
 
Conclusion 
We have presented a series of novel 3-phenoxy substituted β-lactams and evaluated their 
antiproliferative activity and cytotoxicity in MCF-7 breast cancer cells. The most potent 
compounds discovered via the antiproliferative assays were phenolic 78b and amino-
substiuted 90b, and were also found to be minimally cytotoxic. Depolymerization of isolated 
tubulin was demonstrated and confocal microscopy indicated disruption of the tubulin 
network in MCF-7 cells; taken together, these results confirm that the β-lactams are targeting 
tubulin. Further experiements demonstrated that β-lactam 90b interacts with the colchicine-
binding site on β-tubulin. Cell-cycle analysis indicated that 90b caused G2/M arrest and both 
78b and 90b caused apoptosis, typical of microtubule-destabilizing agents. X-Ray 
crystallography studies of selected compounds reveal that the torsional angle between the aryl 
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rings at N-1 and C-4 of the β-lactam is crucial for potent antiproliferative activity. Phosphate 
and amino acid prodrugs of both 78b and 90b were synthesised, of which compound 102b 
retained potency and is a promising candidate for further clinical development.  
  
 21 
 
Experimental Section 
All reagents were commercially available and were used without further purification unless 
otherwise indicated. Anhydrous solvents were obtained by distillation from the indicated 
systems immediately prior to use: THF from sodium/benzophenone, dichloromethane from 
calcium hydride and toluene from sodium. IR spectra were recorded as thin films on NaCl 
plates or as KBr discs on a Perkin-Elmer Paragon 100 FT-IR spectrometer. 1H and 13C NMR 
spectra were obtained on a Bruker Avance DPX 400 instrument at 20oC, 400.13 MHz for 1H 
spectra, 100.61 MHz for 13C spectra, in either CDCl3, CD3COCD3 or CD3OD (internal 
standard: TMS). Low resolution mass spectra were run on a Hewlett-Packard 5973 MSD 
GC–MS system in EI mode, while HRMS for all final compounds were obtained on a 
Micromass Time of Flight mass spectrometer (TOF) equipped with electrospray ionization 
(ES) interface operated in positive ion mode at the High Resolution Mass Spectrometry 
Laboratory by Dr. Martin Feeney in the School of Chemistry, Trinity College Dublin. TLC 
was performed using Merck Silica gel 60 TLC aluminium sheets with fluorescent indicator 
visualizing with UV light at 254nm. Flash chromatography was carried out using standard 
silica gel 60 (230-400 mesh) obtained from Merck. All products isolated were homogenous 
on TLC. The purity of the tested compounds was determined by HPLC or combustion 
analysis and, unless otherwise stated, the purity level was >95%. Elemental analyses were 
performed on an Exetor Analytical CE4400 CHN analyser in the microanalysis laboratory, 
Department of Chemistry, University College Dublin. Analytical high-performance liquid 
chromatography (HPLC) was performed using a Waters 2487 Dual Wavelength Absorbance 
detector, a Waters 1525 binary HPLC pump and a Waters 717plus Autosampler. The column 
used was a Varian Pursuit XRs C18 reverse phase 150 x 4.6mm chromatography column. 
Samples were detected using a wavelength of 254 nm. All samples were analyzed using 
acetonitrile (70%): water (30%) over 10 min and a flow rate of 1 mL/min.  
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3-Hydroxy-4-methoxy-2-nitrobenzaldehyde (8). HNO3 (conc, 12 mmol) was added to a 
stirred solution of isovanillin (10 mmol) in acetone (40 mL) at rt. The reaction mixture was 
stirred for 30 min, poured onto ice water (200 mL) and resulting precipitate filtered via a 
sinter glass funnel. Bright yellow solid; yield 42% yield; mp 186 oC.47 IR (KBr): ν̃ = 1671 
cm-1 (s; ν(C=O)), 3326 cm-1 (s; ν(OH)). 1H NMR (CDCl3): δ 4.09 (s, 3H), 7.15 (d, J=8.5 Hz, 
1H), 7.51 (d, J=8.5 Hz 1H), 10.10 (s, 1H). 13C NMR (CDCl3): δ 59.0, 119.1, 123.6, 129.8, 
139.8, 141.3, 153.3, 187.2. HRMS (ESI): m/z calcd for C8H7NO5 + Na
+ [M + Na]+: 220.0216; 
found: 220.0209. The filtrate was reduced in vacuo and a further precipitate formed was 
found to contain 4:1 mixture of the 3-hydroxy-4-methoxy-2-nitrobenzaldehyde (8) and 3-
hydroxy-4-methoxy-6-nitrobenzaldehyde (7); 5-Hydroxy-4-methoxy-2-nitrobenzaldehyde 
(7) was isolated as a brown solid; yield 31%, mp 142 oC. IR (KBr): ν̃ = 1694 cm-1 (s; 
ν(C=O)), 3332 cm-1 (s; ν(OH)). 1H NMR (CDCl3): δ 4.10 (s, 3H), 6.25 (s, 1H), 7.49 (s, 1H), 
7.68,(s, 1H), 10.44 (s, 1H). 13C NMR (CDCl3): δ 58.3, 109.5, 119.1, 123.5, 144.3, 150.0, 
158.6, 188.7. HRMS (ESI): m/z calcd for C8H7NO5 + Na
+ [M + Na]+: 220.0216; found: 
220.0231. 
Acetic acid 5-formyl-2-methoxyphenyl ester (9). Acetic anhydride (40 mmol), dissolved in 
diethyl ether (40 mL), was added dropwise to a solution of isovanillin (40 mmol), and KOH 
(40 mmol) in water (200 mL) at 0 oC. The reaction was stirred at 0 oC for a further 30 min 
before the resulting precipitate was filtered. White powder; yield 93%, mp 73 oC.48 IR (KBr): 
ν̃ = 1684 cm-1 (s; ν(C=O)), 1769 cm-1 (s; ν(C=O ester). 1H NMR (CDCl3): δ 2.33 (3H, s), 3.91 
(3H, s), 4.82 (1H, s), 7.06 (1H, d, J=8.5 Hz), 7.58-7.76 (2H, m), 9.82, (s, 1H). 13C NMR 
(CDCl3): δ 20.1, 55.8, 111.6, 122.9, 129.8, 139.7, 155.9, 168.3, 189.7. 
Acetic acid 5-formyl-2-methoxy-3-nitrophenyl ester (10). To a stirring solution of HNO3 
(conc., 360 mmol) at -18 oC, 9 (36 mmol) was added in portions over 10 min, and the mixture 
was stirred at -18 oC for 2 min, then at -5 oC for a further 20 min, before being poured onto 
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150 cm3 of crushed ice. The resulting slurry was retained at 5 oC overnight, then filtered. The 
filter cake was washed with water (10 mL×5) and dried to afford the product as a pale yellow 
solid; yield 82%; mp 65 oC. IR (KBr): ν̃ = 1698 cm-1 (s; ν(C=O)), 1778 cm-1 (s; ν(C=O ester). 
1H NMR (CDCl3): δ 2.41 (3H, s), 4.02 (3H, s), 7.85 (1H, d, J=2.0 Hz), 8.20 (1H, d, J=2.0Hz), 
9.93 (1H, s). 13C NMR (CDCl3): δ 20.2, 62.5, 123.6, 127.4, 130.8, 145.1, 150.3, 167.7, 187.8.  
3-Hydroxy-4-methoxy-5-nitrobenzaldehyde (11). Compound 10 (23.5 mmol) was 
dissolved into warm NaOH (5% aq. soln.). The resulting dark red solution was cooled to rt, 
acidified to pH 1 with conc. HCl, which resulted in loss of colour and the formation of a 
precipitate. This mixture was stirred at rt, then cooled to 0 oC. The precipitate was isolated by 
filtration to afford the product as an off-white solid; yield 8%; mp 52-56 oC. IR (KBr) υ max: 
1690 (C=O), 3415 (OH) cm-1. 1H NMR (CDCl3): δ 4.08 (3H, s), 6.59 (1H, s (br), 7.74 (1H, d, 
J=2.0 Hz), 7.98 (1H, d, J=1.5 Hz), 9.94 (1H, s). 13C NMR (CDCl3): δ 62.3, 118.5, 118.8, 
131.3, 142.3, 145.5, 150.9, 188.9. HRMS (ESI): m/z calcd for C8H7NO5 + Na
+ [M + Na]+: 
220.0216; found: 220.0217. 
4-(Azidophenyl)methanol (12). NaNO2 (7.5 mmol) in water (4 mL) was added dropwise to 
a stirring suspension of 4-(aminobenzyl)alcohol (5 mmol) in 2 M H2SO4 (6 mL) at 0 
oC; after 
the addition the reaction became clear and colourless. The solution was stirred for 15 min 
before NaN3 (7.5 mmol) in water (4 mL) was added carefully dropwise over 5 min with 
evolution of gas. The reaction was stirred at rt for a further hour, extracted with diethyl ether 
(10 mL×4); the organic layer was dried over Na2SO4, filtered and the solvent removed in 
vacuo. Clear oil; yield 90%.49 IR (NaCl): ν̃ = 3321 cm-1 (s; ν(OH)), 2117 cm-1 (s; ν(N3)). 1H 
NMR (CDCl3): δ 2.32 (1H, s, broad), 4.64 (2H, s), 7.00 (2H, d, J=8.4 Hz), 7.32 (2H, d, J=8.6 
Hz). 13C NMR (CDCl3): δ 64.1, 118.6, 128.1, 137.1, 138.9. 
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4-Azidobenzaldehyde (13). To a stirred solution of 12 (4.47 mmol) in dry CH2Cl2 (20 mL) 
under nitrogen was added pyridinium chlorochromate (7.6 mmol), and the resulting solution 
was stirred at rt for 1 h. The reaction mixture was diluted with CH2Cl2 (20 mL), filtered 
through a 1 cm silica column and the solvent removed in vacuo to yield the product as an 
orange oil; yield 78%.49 IR (NaCl): ν̃ = 1694 cm-1 (s; ν(C=O)), 2110 cm-1 (s; ν(N3)). 1H NMR 
(CDCl3): δ 7.10 (2H, d, J=8.3 Hz), 7.83 (2H, d, J=8.3 Hz), 9.89 (1H, s). 13C NMR (CDCl3): δ 
119.0, 131.1, 132.7, 190.2.  
General method I: imine preparation 
The appropriately substituted benzaldehyde (10 mmol) and substituted aniline (10 mmol) 
were refluxed together in ethanol (50 mL) for 5 h with a catalytic amount of concentrated 
H2SO4. The reaction mixture was reduced in vacuo and the resulting solid product was 
recrystallised from ethanol. Imines 14, 17, 31 and 40,17 20 and 22,41 15,18 24, 25 and 2625 
were prepared and characterised as described previously by us. 
(3-Methoxybenzylidene)-(3,4,5-trimethoxyphenyl)amine (16) was prepared according to 
general method I from 3-methoxybenzaldehyde and 3,4,5-trimethoxyaniline. Colourless 
solid; yield 88%, mp 59 oC. IR (KBr): ν̃ = 1587 cm-1 (s; ν(C=N)). 1H NMR (CDCl3): δ 3.88 
(s, 3H), 3.90 (s, 6H), 3.92 (s, 3H), 6.51 (s, 2H), 7.32-7.52 (m, 4H), 8.46 (s, 1H). 13C NMR 
(CDCl3): δ 54.9, 55.7, 60.6, 97.7, 111.3, 117.9, 121.8, 129.3, 135.9, 137.0, 147.4, 153.1, 
159.2, 159.6. HRMS (ESI): m/z calcd for C17H19NO4 + H
+ [M + H]+: 302.1387; found: 
302.1403. 
Benzo[1,3]dioxol-5-methylene-(3,4,5-trimethoxyphenyl)amine (18) was prepared 
according to general method I from 3,4,5-trimethoxyaniline and 3,4-
methylenedioxybenzaldehyde. Pale yellow solid; yield 68%; mp 101 oC.15 IR (KBr): ν̃ = 1629 
cm-1 (s; ν(C=N)). 1H NMR (CDCl3): δ 3.86 (s, 3H), 3.89 (s, 6H), 5.93 (s, 2H), 6.05-7.42 (m, 
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5H), 8.35 (s, 1H). 13C NMR (CDCl3): δ 55.4, 55.6, 60.5, 97.6, 101.2, 106.3, 107.8, 125.3, 
130.5, 135.7, 147.5, 148.0, 150.1, 153.4, 158.4. HRMS (ESI): m/z calcd for C17H17NO5 + H
+ 
[M + H]+: 316.1179; found: 316.1186. 
 (4-Bromobenzylidene)-3,4,5-trimethoxyphenylamine (19) was prepared according to 
general method I from 4-bromobenzaldehyde and 3,4,5-trimethoxyaniline. Pale yellow solid; 
yield 70%; mp 110-112 ˚C. IR (KBr): ν̃ = 1624 cm-1 (s; ν(C=N)). 1H NMR (CDCl3): δ 3.89 
(s, 3H), 3.92 (s, 6H), 6.51 (s, 2H), 7.63 (d, J = 8.5 Hz, 2H), 7.79 (d, J = 8.5 Hz, 2H), 8.45 (s, 
1H). 13C NMR (CDCl3): δ 55.7, 60.6, 97.7, 125.5, 129.7, 130.5, 131.6, 132.0, 147.9, 153.2, 
157.8. HRMS (ESI): m/z calcd for C16H16BrNO3 + H
+ [M + H]+: 350.0386; found: 350.0382. 
(3-Fluoro-4-methoxybenzylidene)-(3,4,5-trimethoxyphenyl)amine (21) was prepared 
according to general method I from 3,4,5-trimethoxyaniline and 3-fluoro-4-
methoxybenzaldehyde White solid; yield 84%; mp 100 oC. IR (KBr): ν̃ = 1609 cm-1 (s; 
ν(C=N)). 1H NMR (CDCl3): δ 3.82, (s 3H), 3.91, (s 6H), 3.97 (s 3H), 6.48 (s, 2H), 7.62-7.75, 
(m, 3H), 8.39 (s, 1H). 13C NMR (CDCl3): δ 55.4, 55.6, 60.5, 97.7, 112.3, 114.7, 125.8, 129.2, 
135.9, 147.2, 149.4, 150.8, 153.3, 157.1. HRMS (ESI): m/z calcd for C17H18 FNO4 + H
+ [M + 
H]+: 320.1293; found: 320.1284. 
4-[(3,4,5-Trimethoxyphenylimino)methyl]benzonitrile (23) was prepared according to 
general method I from 3,4,5-trimethoxyaniline and 4-formylbenzonitrile. Pale yellow solid; 
yield 92%; mp 134 oC.50 IR (KBr): ν̃ = 1580 cm-1 (s; ν(C=N)), 2223 cm-1 (s; ν (C≡N)). 1H 
NMR (CDCl3): δ 3.88 (s, 3H), 3.92 (s, 6H), 6.55-8.02 (m, 6H), 8.53 (s, 1H). 13C NMR 
(CDCl3): δ 56.2, 61.1, 98.4, 114.3, 118.5, 129.1, 132.6, 137.2, 139.9, 146.8, 153.7, 157.1. 
HRMS (ESI): m/z calcd for C17H16 N2O3 + H
+ [M + H]+: 297.1234; found: 297.1250. 
(3-Nitrobenzylidene)-(3,4,5-trimethoxyphenyl)amine (27) was prepared according to 
general method I from 3-nitrobenzaldehyde and 3,4,5-trimethoxyaniline. Yellow solid; yield 
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93%; mp 160 oC. IR (KBr): ν̃ = 1588 cm-1 (s; ν(C=N)). 1H NMR (CDCl3): δ 3.89 (s, 3H), 3.93 
(s, 6H), 6.56 (s, 2H), 6.66-6.72 (m, 4H), 8.76 (s, 1H). 13C NMR (CDCl3): δ 55.7, 60.6, 97.9, 
122.9, 125.1, 129.4, 133.6, 136.7, 137.3, 146.1, 148.2, 153.2, 155.9. HRMS (ESI): m/z calcd 
for C16H16N2O5 + H
+ [M + H]+: 317.1132; found: 317.1143. 
(4-Nitrobenzylidene)-(3,4,5-trimethoxyphenyl)amine (28) was prepared according to 
general method I from 4-nitrobenzaldehyde and 3,4,5-trimethoxyaniline. Yellow solid, yield 
82%; mp 158 oC. IR (KBr): ν̃ = 1587 cm-1 (s; ν(C=N)). 1H NMR (CDCl3): δ 3.90 (s, 3H), 3.94 
(s, 6H), 6.57 (s, 2H), 8.09 (d, J=8.0 Hz, 2H), 8.34 (d, J=8.0 Hz, 2H), 8.59 (s, 1H). 13C NMR 
(CDCl3): δ 56.2, 61.1, 98.5, 124.1, 129.3, 137.4, 141.5, 146.7, 149.2, 153.7, 156.5. HRMS 
(ESI): m/z calcd for C16H16N2O5 + H
+ [M + H]+: 317.1132; found: 317.1124. 
(4-Methylsulfanylbenzylidene)-(3,4,5-trimethoxyphenyl)amine (29) was prepared 
according to general method I from 3,4,5-trimethoxyaniline and 4-methylthiobenzaldehyde 
Yellow solid; yield 88%; mp 96 oC. IR (KBr): ν̃ = 1628 cm-1 (s; ν(C=N)). 1H NMR (CDCl3): 
δ 2.52 (s, 3H), 3.87 (s, 3H), 3.89 (s, 6H), 6.48-7.80 (m, 6H), 8.41 (s, 1H). 13C NMR (CDCl3): 
δ 14.5, 55.7, 60.6, 97.7, 125.2, 132.2, 135.8, 142.9, 147.5, 153.1, 158.5. HRMS (ESI): m/z 
calcd for C17H19NO3S + H
+ [M + H]+: 318.1158; found: 318.1162. 
(4-Azidobenzylidene)-(3,4,5-trimethoxyphenyl)amine (30) was prepared from 4-
azidobenzaldehyde (13) and 3,4,5-trimethoxyaniline according to general method I. Yellow 
solid; yield 18%; mp 74 oC. IR (KBr): ν̃ = 1584 cm-1 (s; ν(C=N)), 2120 cm-1 (s; ν(N3)). 1H 
NMR (CDCl3): δ 3.89 (s, 3), 3.92 (s, 6H), 6.51 (s, 2H), 7.14 (d, J=8.3 Hz, 2H), 7.9 (d, J=8.6, 
2H), 8.45 (s, 1H). 13C NMR (CDCl3): 55.9, 57.2, 98.1, 122.6, 127.4, 128.4, 129.9, 133.3, 
135.4, 151.5, 161.1. HRMS (ESI): m/z calcd for C16H16N4O3 + H
+ [M + H]+: 313.1295; 
found: 313.1225. 
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4-[(3,4,5-Trimethoxyphenylimino)methyl]phenol (32) was prepared according to general 
method I from 3,4,5-trimethoxyaniline and 4-hydroxybenzaldehyde. Pale yellow solid; yield 
69% yield; mp 158 oC. IR (KBr): ν̃ = 1624 cm-1 (s; ν(C=N)), 3398 cm-1 (s; ν (OH)). 1H NMR 
(CDCl3): δ 3.87 (s, 3H), 3.89 (s 6H), 6.48, (s, 2H), 7.26-7.76 (m, 4H), 8.39 (s, 1H). 13C NMR 
(CDCl3): δ 55.6, 55.6, 60.6, 97.7, 108.0, 113.9, 124.8, 128.4, 135.6, 146.8, 147.6, 148.7, 
153.5, 159.1. HRMS (ESI): m/z calcd for C16H17 NO4 + H
+ [M + H]+: 288.1230; found: 
288.1235. 
4-[(3,4,5-Trimethoxyphenylimino)methyl]benzene-1,2-diol (33) was prepared according to 
general method I from 3,4,5-trimethoxyaniline and 3,4-dihydroxybenzaldehyde. White solid; 
yield 82%; mp 58 oC. IR (KBr): ν̃ = 1645 cm-1 (s; ν(C=N)), 3401 cm-1 (s; ν (OH)). 1H NMR 
(CDCl3): δ 3.78 (s, 3H), 3.88 (s, 6H), 4.90 (s, (br), 1H), 6.55 (s, 2H), 7.31-7.42 (m, 3H), 8.38 
(s, 1H). 13C NMR (CDCl3): δ 54.4, 54.7, 59.4, 97.6, 112.9, 114.4, 117.6, 122.6, 127.5, 135.3, 
142.1, 135.7, 153.0, 160.6. HRMS (ESI): m/z calcd for C16H17NO5 + H
+ [M + H]+: 304.1179; 
found: 304.1181. 
2-Methoxy-4-[(3,4,5-trimethoxyphenylimino)methyl]phenol (34) was prepared according 
to general method I from 3,4,5-trimethoxyaniline and 4-hydroxy-3-methoxybenzaldehyde. 
Pale yellow solid; yield 61%; mp 140 oC. IR (KBr): ν̃ = 1613 cm-1 (s; ν(C=N)), 3403 cm-1 (s; 
ν (OH)). 1H NMR (CDCl3): δ 3.87 (s, 6H), 3.91 (s, 6H), 3.07 (s, 3H), 6.48-7.61 (m, 5H), 6.36 
(s (br), 1H), 8.37 (s, 1H). 13C NMR (CDCl3): δ 56.0, 61.0, 98.1, 108.5, 114.4, 125.3, 128.8, 
136.1, 147.3, 148.1, 149.2, 153.6, 159.7. HRMS (ESI): m/z calcd for C17H19NO5 + H
+ [M + 
H]+: 318.1336; found: 318.1341. 
3-[(3,4,5-Trimethoxyphenylimino)methyl]phenol (35) was prepared according to general 
method I from 3-hydroxybenzaldehyde and 3,4,5-trimethoxyaniline. White solid; yield 73%, 
mp 121 oC. IR (KBr): ν̃ = 1583 cm-1 (s; ν(C=N)), 3327 cm-1 (s; ν (OH)). 1H NMR (CDCl3): δ 
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3.76 (s, 3H), 3.88 (s, 6H), 6.50 (s, 2H) 7.33-7.42 (m, 4H), 7.00 (s(br), 1H), 8.40 (s, 1H). 13C 
NMR (CDCl3): δ 55.7, 60.6, 97.8, 114.1, 118.8, 121.5, 129.6, 136.1, 136.7, 147.1, 153.1, 
156.0, 159.8. HRMS (ESI): m/z calcd for C16H17NO4 + H
+ [M + H]+: 288.1230; found: 
288.1249. 
2-Methoxy-5-[(4-methoxyphenylimino)methyl]phenol (36) was prepared according to 
general method I from 4-methoxyaniline and 3-hydroxy-4-methoxybenzaldehyde. Pale 
yellow solid; yield 95%; mp 112-114 oC.51 IR (KBr): ν̃ = 1576 cm-1 (s; ν(C=N)). 1H NMR 
(CDCl3): δ 3.81 (s, 3H), 3.91 (s, 3H), 5.86, (br s, 1H), 6.92-7.51 (m, 7H), 8.38 (s, 1H). 13C 
NMR (CDCl3): δ 55.1, 55.6, 109.9, 113.3, 113.9, 121.5, 121.7, 129.8, 144.6, 145.5, 148.7, 
157.6, 157.6. HRMS (ESI): m/z calcd for C15H15NO3 + H
+ [M + H]+: 258.1125; found: 
258.1122. 
6-Methoxy-2-nitro-3-[(3,4,5-trimethoxyphenylimino)methyl]phenol (37) was prepared 
from 8 and 3,4,5-trimethoxyaniline according to general method I. Yellow powder; yield 
23%; mp 136 oC. IR (KBr): ν̃ = 1578 cm-1 (s; ν(C=N)), 3275 cm-1 (s; ν(OH)). 1H NMR 
(CDCl3): δ 1.73 (1H, s), 3.87 (3H, s), 3.91 (6H, s), 4.01 (3H, s), 6.51 (2H, s), 7.11 (1H, d, 
J=8.5 Hz), 7.66 (1H, d, J=8.5 Hz), 8.61 (1H, s). 13C NMR (CDCl3): δ 55.4, 56.5, 60.6, 97.9, 
113.8, 120.4, 122.9, 135.8, 136.4, 142.3, 146.6, 150.4, 153.4, 154.3. HRMS (ESI): m/z calcd 
for C17H18N2O7 + H
+ [M + H]+: 363.1187; found: 363.1180. 
2-Methoxy-4-nitro-5-[(3,4,5-trimethoxyphenylimino)methyl]phenol (38) was prepared 
from 7 and 3,4,5-trimethoxyaniline according to general method I. Yellow powder; yield 
10%, mp 188 oC. IR (KBr): ν̃ = 1583 cm-1 (s; ν(C=N)), 3428 cm-1 (s; ν(OH)). 1H NMR 
(CDCl3): δ 3.88 (3H, s), 3.92 (6H, s), 4.03 (3H, s), 6.56 (2H, s), 7.67 (1H, s), 7.76 (1H, s), 
9.01 (1H, s). 13C NMR (CDCl3): δ 55.5, 55.7, 60.6, 98.1, 106.9, 113.9, 126.5, 136.5, 141.4, 
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146.5, 147.5, 150.1, 153.1, 155.2. HRMS (ESI): m/z calcd for C17H18N2O7 + H
+ [M + H]+: 
363.1187; found: 363.1178. 
2-Methoxy-3-nitro-5-[(3,4,5-trimethoxyphenylimino)methyl]phenol (39) was prepared 
from 11 and 3,4,5-trimethoxyaniline according to general method I. Yellow solid; yield 47%; 
mp 105 oC. IR (KBr): ν̃ = 1592 cm-1 (s; ν(C=N)), 3420 cm-1 (s; ν(OH)). 1H NMR (CDCl3): δ 
3.83 (s, 3H), 3.90 (s, 6H), 4.05 (s, 3H), 6.53 (s, 2H), 7.82 (d, J=1.7 Hz, 1H), 7.99 (d, J=1.7 
Hz, 1H), 8.42 (s, 1H). 13C NMR (CDCl3): δ 55.4, 55.7, 60.6, 62.4, 97.9, 117.0, 118.6, 131.9, 
136.6, 142.3, 142.8, 146.2, 150.5, 153.2, 155.5. HRMS (ESI): m/z calcd for C17H18N2O7 + H
+ 
[M + H]+: 363.1187; found: 363.1184. 
General method II: synthesis of TBDMS-protected imines  
DBU was added dropwise to a solution of imine (5 mmol) and tert-butyldimethylsilylchloride 
(6 mmol) stirring in anhydrous CH2Cl2 (40 mL) under a nitrogen atmosphere. The reaction 
was stirred under N2 at rt until the disappearance of starting material (as indicated by TLC; 2 
- 4 h). The reaction was diluted with CH2Cl2 (50 mL) and washed with water (100 mL×2), 
0.1M HCl (50 mL×2), and saturated aq. NaHCO3 (50 mL×2), before drying over anhydrous 
Na2SO4. The solvent was removed in vacuo to yield TBDMS-protected imine, which was 
used in the subsequent -lactam syntheses without further purification. Imines 4017 and 4318 
was characterised as described by us previously.  
[4-(tert-Butyldimethylsilanyloxy)benzylidene]-(3,4,5-trimethoxyphenyl)amine (41) was 
was prepared from 32 according to general method II. Amber oil; yield 91%. IR (NaCl): ν̃ = 
1581 cm-1 (s; ν(C=N)). 1H NMR (CDCl3): 0.21 (6H, s), 1.01 (9H, s), 3.88 (3H, s), 3.91 (6H, 
s), 6.48 (2H, s), 6.94 (2H, d), 7.79 (2H, d), 8.41 (1H, s). 13C NMR (CDCl3): δ -5.9, 18.1, 25.3, 
55.1, 56.0, 61.0, 98.1, 108.5, 114.4, 125.3, 128.8, 136.1, 147.3, 148.1, 149.3, 153.6, 159.7. 
HRMS (ESI): m/z calcd for C22H31NO4Si
+ [M]+: 401.2022; found: 401.2031. 
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[3,4-Bis-(tert-butyldimethylsilanyloxy)benzylidene]-(3,4,5-trimethoxyphenyl)amine (42) 
was prepared from 33 according to general method II. Colourless oil, yield 88%. IR (NaCl): ν̃ 
= 1598 cm-1 (s; ν(C=N)). 1H NMR (CDCl3): δ 0.25 (12H, s), 1.05 (18H, s), 3.87 (3H, s), 3.92 
(6H, s), 6.47 (2H, s), 7.28 (1H, s), 7.40 (2H, m), 8.32 (1H, s). 13C NMR (CDCl3): δ -5.9, -5.9, 
18.0, 18.1, 25.3, 54.9, 55.4, 60.6, 91.9, 111.2, 120.0, 123.7, 129.0, 137.6, 142.4, 147.0, 151.5, 
154.6, 158.8. HRMS (ESI): m/z calcd for C28H45NO5Si2
+ [M]+: 531.2836; found: 531.2839. 
[3-(tert-Butyldimethylsilanyloxy)benzylidene]-(3,4,5-trimethoxyphenyl)amine (44) was 
prepared from 35 according to general method II and was used without further 
characterization to prepare 69. Amber oil; yield 92%. IR (NaCl): ν̃ = 1597 cm-1 (s; ν(C=N)). 
1H NMR (CDCl3): 0.23 (s, 3H), 0.24 (s, 3H), 1.00 (s, 9H), 3.87 (s, 3H), 3.90 (s, 6H), 6.50 (s, 
2H), 6.97 (1H, dd, J=2.2 Hz, 7.7 Hz), 7.34-7.41 (m, 3H), 8.42 (s, 1H). 13C NMR (CDCl3): δ -
4.9, -4.8, 17.7, 25.2, 53.0, 55.6, 60.5, 97.7, 119.3, 121.9, 122.9, 129.3, 135.9, 137.1, 147.5, 
153.1, 155.7, 159.2.  
1-(3-((tert-Butyldimethylsilyl)oxy)-4-methoxyphenyl)-N-(4-
methoxyphenyl)methanimine (45) was prepared from 36 according to general method II 
and was used without further characterization to prepare 74. Clear oil; yield 83%. IR (NaCl): 
ν̃ = 1574 cm-1 (s; ν(C=N)). 1H NMR (CDCl3): δ 0.22 (s, 6H), 1.05 (s, 9H), 3.85 (s, 3H), 3.91 
(s, 3H), 6.93-7.45 (m, 7H), 8.39 (s, 1H). 13C NMR (CDCl3): δ -4.5, 18.5, 27.7, 55.4, 55.5, 
111.4, 114.3, 120.2, 122.1, 123.7, 129.7, 145.2, 153.8, 153.8, 157.9. 
[3-(tert-Butyldimethylsilanyloxy)-4-methoxy-2-nitrobenzylidene]-(3,4,5-trimethoxy-
phenyl)amine (46) was prepared from 37 according to general method II and was used 
without further characterization to prepare 71. Amber oil; yield 88%. IR (NaCl): ν̃ = 1579 
cm-1 (s; ν(C=N)). 1H NMR (CDCl3): δ 0.26 (6H, s), 1.04 (9H, s), 3.89 (3H, s), 3.93 (6H, s), 
3.97 (3H, s), 6.56 (2H, s), 7.64 (d, J=2 Hz, 2H), 8.99 (1H, s). 13C NMR (CDCl3): δ -4.9, 17.3, 
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25.1, 55.5, 55.7, 60.6, 98.1, 107.7, 119.6, 123.4, 136.4, 142.5, 146.9, 149.8, 152.1, 153.1, 
154.9. 
[5-(tert-Butyldimethylsilanyloxy)-4-methoxy-2-nitrobenzylidene]-(3,4,5-trimethoxy-
phenyl)amine (47) was prepared from 38 according to general method II and was used 
without further characterization to prepare 73. Amber oil; yield 87%. IR (NaCl): ν̃ = 1583 
cm-1 (s; ν(C=N)). 1H NMR (CDCl3): δ 0.25 (6H, s), 1.06 (9H, s), 3.86 (3H, s), 3.94 (6H, s), 
4.08 (3H, s), 6.59 (2H, s), 7.64 (1H, s), 7.81 (1H, s), 8.11 (1H, s). 13C NMR (CDCl3): δ -4.8, 
17.4, 25.2, 55.5, 55.8, 60.9, 98.0, 119.9, 122.9, 128.4, 133.8, 137.3, 147.6, 149.7, 151.1, 
153.9, 158.8. 
[3-(tert-Butyldimethylsilanyloxy)-4-methoxy-5-nitrobenzylidene]-(3,4,5-trimethoxy-
phenyl)amine (48) was prepared from 39 according to general method II and was used 
without further characterization to prepare 72. Amber oil; yield 91%. IR (NaCl): ν̃ = 1596 
cm-1 (s; ν(C=N)). 1H NMR (CDCl3): δ 0.23 (s, 6H), 0.96 (s, 9H), 3.86 (s, 3H), 3.93 (s, 6H), 
4.03 (s, 3H), 6.52 (s, 2H), 7.04 (d, J=1.7 Hz, 1H), 7.68 (d, J=1. Hz, 1H), 8.27 (s, 1H). 13C 
NMR (CDCl3): δ -4.6, -4.0, 18.1, 25.1, 55.3, 55.4, 56.4, 60.6, 97.8, 120.1, 121.2 , 131.9, 
137.7, 146.7, 151.1, 152.3, 153.1, 154.2, 161.3. 
Synthesis of β-Lactams; General Method  III.A: To a refluxing solution of the appropriate 
imine (5 mmol) and triethylamine (6 mmol) in anhydrous CH2Cl2 (40 mL) was added a 
solution of the appropiate acid chloride (6 mmol) in anhydrous CH2Cl2 (10 mL) over 45 min 
under nitrogen. The reaction was refluxed for 5 h, continuously stirred under nitrogen, and 
stirred overnight until the starting material had disappeared as monitored by TLC. The 
reaction mixture was cooled to rt and washed with water (100 mL×2), dried over anhydrous 
Na2SO4 and solvent was removed in vacuo. The crude product was purified by flash 
chromatography over silica gel (1:1; n-hexane: ethyl acetate). 
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General Method III.B: A solution of the imine (1 mmol) and triethylamine (1.2 mmol) in 
dichloroethane (10 mL) heated to 40 oC by microwave irradiation at atmospheric pressure 
and under a nitrogen atmosphere. To this solution, the appropriate acid chloride (1.2 mmol) 
in dichloroethane (5 mL) was added dropwise over 45 min. Upon completion of the addition, 
the reaction temperature was maintained at 40 oC by continous microwave irradiation, while 
maintaining the nitrogen atmosphere. A characteristic darkening of the reaction was noticed 
upon completion of the reaction. The reaction was washed with water (100 mL×2), dried over 
Na2SO4 before the solvent was removed under reduced pressure. The crude product was 
purified by flash chromatography over silica gel (1:1, n-hexane: ethyl acetate). 
General method III.C: The imine (5 mmol) and phenoxyacetyl chloride (5 mmol) were 
dissolved in dry toluene (15 mL), under nitrogen and stirring at 0 ºC. The solution was 
allowed to reach rt and warmed to 100 ºC. Triethylamine (5.5 mmol) was added dropwise. 
The mixture was refluxed at 100 ºC for 5 h. The solution was concentrated in vacuo and the 
residue was purified by flash chromatography over silica gel eluted with 4:1 n-hexane: ethyl 
acetate as eluent. 
Cis-3-Phenoxy-1,4-bis-(3,4,5-trimethoxyphenyl)azetidin-2-one (49) was obtained from 14 
according to general method III.A. White solid; yield 32%; mp 132-134 oC. IR (KBr): ν̃ = 
1762 cm-1 (s; ν(C=O)). 1H NMR (CDCl3): δ 3.75 (s 12H), 3.79 (s, 6H), 5.20 (d, 1H, J=5.0 
Hz), 5.60 (d, 1H, J=5.0 Hz), 6.57 (s, 2H), 6.98-7.19 (m, 7H). 13C NMR (CDCl3): δ 55.0, 55.5, 
60.5, 62.0, 80.5, 95.0, 102.5, 115.0, 122.0, 127.5, 129.0, 132.5, 134.5, 138.2, 152.5, 153.1, 
156.0, 162.7. HRMS (ESI): m/z calcd for C27H29NO8 + Na
+ [M + Na]+: 518.1785; found: 
518.1786. 
4-(4-Methoxyphenyl)-3-phenoxy-(3,4,5-trimethoxyphenyl)azetidin-2-one (50) was 
obtained from 15 according to general method III.A. Trans isomer 50b was isolated as white 
solid; yield 21%; mp 112-114 oC. IR (KBr): ν̃ = 1740 cm-1 (s; ν(C=O)). 1H NMR (CDCl3): δ 
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3.72 (s, 6H), 3.79 (s, 3H), 3.87 (s, 3H), 4.95 (d, 1H, J= 2.2 Hz), 5.13 (d, 1H, J= 2.2 Hz), 6.58-
7.28 (m, 11H). 13C NMR (CDCl3): δ 54.9, 55.6, 63.6, 60.5, 86.7, 94.9, 114.4, 114.9, 121.8, 
126.9, 127.4, 129.2, 132.7, 134.4, 153.0, 156.5, 159.8, 162.1. HRMS (ESI): m/z calcd for 
C25H25NO6 + Na
+ [M + Na]+: 458.1574; found: 458.1580. 
Cis isomer 50a was isolated as a white solid; yield 33%; mp 155 oC. IR (KBr): ν̃ = 1741 cm-1 
(s; ν(C=O)). 1H NMR (CDCl3): δ 3.74 (s, 6H), 3.78 (s, 3H), 3.79 (s, 3H), 5.34 (d, 1H, J=5.0 
Hz), 5.54 (d, 1H, J=5.0 Hz), 6.58-7.28 (m, 11H). 13C NMR (CDCl3): δ 55.2, 56.1, 60.9, 62.1, 
81.1, 95.3, 113.9, 115.7, 122.2, 124.4, 129.3, 129.5, 133.1, 134.9, 153.5, 156.9, 159.9, 163.0. 
HRMS (ESI): m/z calcd for C25H25NO6 + Na
+ [M + Na]+: 458.1574; found: 458.1576. 
Cis-4-(3-Methoxyphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (51) was 
obtained from 16 according to general method III.A. Colourless solid; yield 34%; mp 158 oC. 
IR (KBr): ν̃ = 1749 cm-1 (s; ν(C=O)). 1H NMR (CDCl3): δ 3.76 (s, 6H), 3.81 (s, 6H), 5.32 (d, 
J=5.1 Hz, 1H), 5.57 (d, J=5.1 Hz, 1H), 6.67 (s, 2H), 6.82-7.29 (m, 9H). 13C NMR (CDCl3): δ 
56.1, 60.9, 62.5, 81.0, 95.3, 110.3, 114.2, 115.6, 121.9, 122.3, 124.4, 129.4, 133.2, 134.9, 
146.2, 146.7, 153.5, 156.9, 163.0. HRMS (ESI): m/z calcd for C25H25NO6 + Na
+ [M + Na]+: 
458.1574; found: 458.1574. 
Cis-4-(3,4-Dimethoxyphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (52) 
was obtained from 17 according to general method III.A. White solid; yield 56%, mp 152 oC. 
IR (KBr): ν̃ = 1751 cm-1 (s; ν(C=O)). 1H NMR (CDCl3): δ 3.75 (s, 6H), 3.79 (s, 6H), 3.85 (s, 
3H), 5.33 (d, J=5.0 Hz, 1H), 5.58 (d, J= 4.5 Hz, 1H), 6.66-6.99 (10H, m). 13C NMR (CDCl3): 
δ 55.1, 55.9, 60.3, 62.6, 80.2, 95.9, 110.9, 115.4, 120.1, 122.4, 124.7, 129.7, 133.3, 134.2, 
148.9, 156.4, 162.1. HRMS (ESI): m/z calcd for C26H27NO7 + Na
+ [M + Na]+: 488.1680; 
found: 488.1697. 
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Cis-4-Benzo[1,3]dioxol-5-yl-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (53) 
was obtained from 18 according to general method III.A. Pale yellow soild; yield 71%; mp 
156 oC. IR (KBr): ν̃ = 1747 cm-1 (s; ν(C=O)). 1H NMR (CDCl3): δ 3.75 (s, 6H), 3.79 (s, 3H), 
5.32 (d, 1H, Jcis=5.0 Hz), 5.51 (d, 1H , Jcis=5.0 Hz), 5.95 (s, 2H), 6.64-7.28 (m, 10H). 
13C 
NMR (CDCl3): δ 56.0, 60.5, 62.1, 80.6, 95.4, 101.7, 107.5, 115.8, 121.5, 122.3, 126.4, 129.6, 
132.7, 134.9, 147.4, 153.4, 156.7, 162.8. HRMS (ESI): m/z calcd for C50H46N2O14 + Na
+ [2M 
+ Na]+: 921.2841; found: 921.2844. 
Cis-4-(4-Bromophenyl)-1-(3,4,5-trimethoxyphenyl)-3-phenoxyazetidin-2-one (54) was 
obtained from 19 according to general method III.A. Colourless solid; yield 61%; mp 125-
127 ˚C. IR (KBr): ν̃ = 1759 cm-1 (s; ν(C=O)). 1H NMR (CDCl3): δ 3.75 (s, 6H), 3.79 (s, 3H), 
5.35 (d, J = 5.0 Hz), 5.58 (d, J = 5.0 Hz), 6.59 (s, 2H), 6.80-7.47 (m, 9H), 13C NMR (CDCl3): 
δ 55.6, 60.5, 61.2, 80.4, 94.7, 115.1, 122.0, 122.5, 128.9, 129.3, 131.3, 131.4, 132.3, 134.6, 
153.1, 156.3, 162.3. HRMS (ESI): m/z calcd for C24H22BrNO5 + H
+ [M + H]+: 484.0754; 
found: 484.0735. 
4-(3-Bromo-4-methoxyphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (55) 
was obtained from 20 according to general method III.A. Cis isomer 55a was isolated as a 
white solid; yield 61%; mp 158oC. IR (KBr): ν̃ = 1756 cm-1 (s; ν(C=O)).1H NMR (CDCl3): δ 
3.76 (s, 6H), 3.80 (s, 3H), 3.87 (s, 3H), 5.29 (d, J = 5.2 Hz), 5.55 (d, J = 5.2 Hz, 1H), 6.62-
7.35, (m, 10H). 13C NMR (CDCl3): δ 55.7, 55.8, 60.5, 60.9, 80.5, 94.8, 111.1, 111.2, 115.2, 
121.9, 125.6, 127.9, 128.9, 132.4, 132.6, 134.6, 153.1, 155.7, 156.3, 162.3. HRMS (ESI): m/z 
calcd for C25H24BrNO6 + Na
+ [M + Na]+: 536.0679; found: 536.0701. 
Trans isomer 55b was isolated as a white solid; yield 31%; mp 170oC. IR (KBr): ν̃ = 1753 
cm-1 (s; ν(C=O)). 1H NMR (CDCl3) δ 3.73, (s, 6H), 3.79 (s, 3H), 3.94 (s, 3H), 4.92 (d, J=2.0 
Hz, 1H), 5.12 (d, J=2.0 Hz, 1H), 6.57-7.64 (m, 11H). 13C NMR (CDCl3): δ 55.6, 55.9, 60.5, 
62.8, 86.7, 94.9, 111.9, 112.3, 114.9, 120.0, 126.3, 128.6, 129.3, 131.0, 132.4, 134.7, 153.1, 
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156.1, 156.5, 161.9. HRMS (ESI): m/z calcd for C25H24BrNO6 + Na
+ [M + Na]+: 536.0679; 
found: 536.0676. 
Cis-4-(3-Fluoro-4-methoxyphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 
(56) was obtained from 21 according to general method III.A. White solid; yield 56%; mp 
120 oC. IR (KBr): ν̃ = 1752 cm-1 (s; ν(C=O)). 1H NMR (CDCl3): δ 3.75 (s, 6H), 3.86 (s, 3H), 
3.86 (s, 3H), 5.30 (d, 1H, J=5.0 Hz), 5.52 (d, 1H, J=5.0 Hz), 6.6-7.1 (m, 10H). 13C NMR 
(CDCl3): δ 55.5, 60.3, 61.5, 80.3, 94.5, 112.7, 115.8, 115.5, 121.2, 113.3, 125.7, 129.6, 132.6, 
134.8, 147.2, 153.9, 156.6, 162.0. HRMS (ESI): m/z calcd for C50H48F2N2O12 + Na
+ [2M + 
Na]+: 929.3068; found: 929.3057. 
Cis-4-(4-Dimethylaminophenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 
(57) was obtained from 22 according to general method III.A. Pale brown solid; yield 34%; 
mp 166 oC. IR (KBr): ν̃ = 1744 cm-1 (s; ν(C=O)). 1H NMR (CDCl3): δ 2.92 (s, 6H), 3.72 (s, 
6H), 3.74 (s, 3H), 5.32 (d, J=5.1 Hz, 1H), 5.51 (d, J=5.1 Hz, 1H), 6.62 (s, 2H), 6.87-7.11 
(9H, m). 13C NMR (CDCl3): δ 40.5, 55.1, 60.9, 62.7, 81.7, 97.9, 111.4, 114.9, 119.4, 121.7, 
128.1, 129.3, 132.5, 134.7, 150.5, 152.4, 156.6, 162.9. HRMS (ESI): m/z calcd for 
C26H28N2O5 + H
+ [M + H]+: 449.2071; found: 449.2096. 
4-[4-Oxo-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-yl]benzonitrile (58) was 
obtained from 23 according to general method III.A. Cis isomer 58a isolated as a white solid; 
yield 37%; mp 174 oC. IR (KBr): ν̃ = 1765 cm-1 (s; ν(C=O)), 2237 cm-1 (s; ν(C≡N)). 1H NMR 
(CDCl3): δ 3.75 (s, 6H), 3.80 (s, 3H), 5.44 (d, J=5.0 Hz, 1H), 5.64 (d, J = 5.0 Hz, 1H), 6.56-
7.63 (m, 11H). 13C NMR (CDCl3): δ 55.7, 60.5, 61.0, 80.5, 94.7, 112.3, 114.9, 117.9, 122.2, 
128.3, 129.1 131.8, 132.1, 135.1, 137.9, 153.3, 155.9, 161.9. HRMS (ESI): m/z calcd for 
C25H22N2O5 + Na
+ [M + Na]+: 453.1421; found: 453.1427. 
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Trans isomer 58b isolated as an off-white solid; yield 24%; mp 162 oC. IR (KBr): ν̃ = 1760 
cm-1 (s; ν(C=O)), 2227 cm-1 (s; ν(C≡N)). 1H NMR (CDCl3): δ 3.72 (s, 6H), 3.79 (s, 3H), 5.08 
(d, J=1.5 Hz, 1H), 5.12 (d, J=1.5 Hz, 1H), 6.50 (s, 2H), 6.88-7.76 (m, 9H). 13C NMR 
(CDCl3): δ 55.7, 60.5, 63.0, 86.6, 94.8, 112.9, 115.0, 117.6, 122.4, 126.7, 129.4, 132.0, 132.8, 
134.9, 140.6, 153.3, 156.3, 161.5. HRMS (ESI): m/z calcd for C25H22N2O5 + Na
+ [M + Na]+: 
453.1421; found: 453.1435. 
Cis-4-Naphthalen-2-yl-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (59) was 
obtained from 24 according to general method III.A. White solid; yield 42%; mp 162 oC. IR 
(KBr): ν̃ = 1746 cm-1 (s; ν(C=O)). 1H NMR (CDCl3): δ 3.71 (s, 6H), 3.78 (s, 3H), 5.57 (d, 
J=5.2 Hz, 1H), 5.67 (d, J=5.2 Hz, 1H), 6.68-7.81 (m, 14H). 13C NMR (CDCl3): δ 55.5, 60.5, 
62.1, 80.9, 94.8, 115.3, 121.9, 124.8, 125.9, 127.3, 127.4, 127.9, 128.9, 129.9, 132.6, 132.7, 
134.5, 153.1, 156.5, 162.7. HRMS (ESI): m/z calcd for C28H25NO5 + Na
+ [M + Na]+: 
478.1625; found: 478.1647. 
Cis-4-Naphthalen-1-yl-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (60) was 
obtained from 25 according to general method III.A. Off-white solid; yield 98%; mp 182-186 
oC. IR (KBr): ν̃ = 1757 cm-1 (s; ν(C=O)). 1H NMR (CDCl3): δ 3.70 (s, 6H), 3.84 (s, 3H), 5.77 
(d, 1H), 6.17 (d, 1H), 6.68-7.85, (m, 14H). 13C NMR (CDCl3): δ 55.7, 60.6, 81.7, 94.8, 116.1, 
121.9, 124.9, 125.4, 125.9, 127.7, 127.8, 128.6, 130.9, 132.9, 132.9, 133.2, 134.3, 153.2, 
156.9, 163.3. HRMS (ESI): m/z calcd for C28H25NO5 + Na
+ [M + Na]+: 478.1625; found: 
478.163. 
4-(4-Methoxy-3-nitrophenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (61) 
was obtained from 26 according to general method III.A. Cis isomer 61a was isolated as a 
pale brown solid; yield 52%; mp 136-138 oC. IR (KBr): ν̃ = 1758 cm-1 (s; ν(C=O)). 1H NMR 
(CDCl3): δ 3.76 (s, 3H), 3.79 (s, 6H), 3.93 (s, 3H), 5.41 (d, J=5.0 Hz, 1H), 5.60 (d, J=5.0 Hz, 
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1H), 6.59 (s, 2H), 7.23 -7.92 (m, 8H). 13C NMR (CDCl3): δ 55.7, 56.2, 60.3, 60.4, 80.4, 94.7, 
113.3, 114.9, 122.2, 124.7, 125.3, 129.1, 132.2, 133.2, 134.8, 138.7, 152.8, 153.2, 156.0, 
162.1. HRMS (ESI): m/z calcd for C25H24N2O8 + Na
+ [M + Na]+: 503.1425; found: 503.1433. 
Trans isomer 61b was isolated as a pale brown solid; yield 26% yield; mp 160 oC. IR (KBr): 
ν̃ = 1753 cm-1 (s; ν(C=O)). 1H NMR (CDCl3): δ 3.76 (s, 6H), 3.80 (3H, s), 4.02 (s, 3H), 5.03 
(d, J=1.5 Hz, 1H), 5.14 (d, J=1.5 Hz, 1H), 6.61 (s, 2H), 7.28-7.92 (m, 8H). 13C NMR 
(CDCl3): δ 55.7, 56.3, 60.5, 62.3, 86.6, 94.9, 114.3, 114.9, 122.3, 123.6, 127.5, 129.4, 131.3, 
132.0, 134.9, 139.5, 152.9, 153.2, 156.3, 161.6. HRMS (ESI): m/z calcd for C25H24N2O8 + 
Na+ [M + Na]+: 503.1425; found: 503.1418. 
Cis-4-(3-Nitrophenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (62) was 
obtained from 27 according to general method III.A. Brown solid; yield 47%; mp 170-174 
oC. IR (KBr): ν̃ = 1762 cm-1 (s; ν(C=O)). 1H NMR (CDCl3): δ 3.76 (s, 3H), 3.80 (s, 6H), 5.53 
(d, J=5 Hz, 1H), 5.68 (d, J=5 Hz, 1H), 6.60 (s, 2H), 7.34-8.27 (m, 9H). 13C NMR (CDCl3): δ 
55.7, 60.5, 60.7, 80.4, 94.7, 114.9, 122.2, 122.7, 123.5, 129.2, 132.1, 133.4, 134.8, 134.9, 
147.7, 153.3, 155.8, 161.9. HRMS (ESI): m/z calcd for C24H22N2O7 + Na
+ [M + Na]+: 
473.1319; found: 473.1325. 
Cis-4-(4-Nitrophenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (63) was 
obtained from 28 according to general method III.A. Colourless solid; yield 39%, mp 154 oC. 
IR (KBr) υ max: 1765 cm-1 (C=O). 1H NMR (CDCl3): δ 3.75 (s, 3H), 3.80 (s, 6H), 5.51 (d, J= 
5.0 Hz, 1H), 5.66 (d, J=5.6 Hz, 1H), 6.57-8.20 (m, 11H). 13C NMR (CDCl3): δ 55.7, 60.5, 
60.8, 80.6, 94.7, 114.9, 122.3, 123.2, 128.5, 129.1, 132.1, 139.9, 147.7, 153.3, 155.9, 161.9. 
HRMS (ESI): m/z calcd for C24H22N2O7 + Na
+ [M + Na]+: 473.1319; found: 473.1335. 
Cis-(4-Methylsulfanylphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (64) 
was obtained from 29 according to general method III.A. Pale yellow solid; yield 77%; mp 
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130 oC. IR (KBr): ν̃ = 1744 cm-1 (s; ν(C=O)). 1H NMR (CDCl3): δ 2.45 (s, 3H), 3.74 (s, 1H), 
3.79 (s, 1H), 5.34 (d, 1H), 5.55 (d, 1H), 6.57-7.17 (m, 11H). 13C NMR (CDCl3): δ 15.7, 55.7, 
60.4, 61.5, 80.3, 94.6, 115.1, 121.6, 125.6, 128.4, 128.2, 132.8, 134.2, 139.6, 153.9, 156.3, 
162.2. HRMS (ESI): m/z calcd for C50H50N2O10S2 + Na
+ [2M + Na]+: 925.2799; found: 
925.2841. 
Cis-4-(4-Azidophenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (65) was 
obtained from 30 according to general method III.A. Grey solid; yield 64%; mp 134-138oC. 
IR (KBr) υ max: 1761 cm-1 (C=O), 2136 cm-1 (-N3). 1H NMR (CDCl3): δ 3.75 (s, 6H), 3.80 
(s, 3H), 5.37 (d, J=4.8 Hz, 1H), 5.57 (d, J=4.8 Hz, 1H), 6.61 (s, 2H), 6.82 (d, J=7.9, 2H), 6.97 
(m, 3H, ArH), 7.20 (d, J=8.3 Hz, 8.8 Hz, 2H), 7.40 (d, J=8.2 Hz, 2H). 13C NMR (CDCl3): δ 
55.6, 55.7, 60.5, 61.3, 80.5, 94.8, 115.1, 118.7, 121.9, 128.9, 128.9, 129.2, 132.5, 134.6, 
140.2, 153.1, 156.3, 162.3. HRMS (ESI): m/z calcd for C24H22N4O5 + Na
+ [M + Na]+: 
469.1482; found: 469.1500. 
4-[3-(t-Butyldimethylsilanyloxy)-4-methoxyphenyl]-3-phenoxy-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (66) was obtained from 40 according to general method 
III.A. Cis isomer 66a was isolated as a white resin; yield 61%. IR (NaCl): ν̃ = 1729 cm-1 (s; 
ν(C=O)). 1H NMR (CDCl3): δ 0.04 (6H, s), 0.91 (9H, s), 3.72 (3H, s), 3.74 (6H, s), 3.91 (3H, 
s), 5.28 (1H, d, J=5 Hz), 5.52 (1H, d, J=5 Hz), 6.64-6.89 (10H, m). 13C NMR (CDCl3): δ -
4.2, , 17.9, 23.5, 55.4, 55.7, 60.6, 61.9, 81.1, 94.9, 113.6, 114.5, 117.4, 119.4, 120.3, 125.1, 
128.0, 132.4, 137.8, 142.0, 148.3, 151.2), 156.7, 162.7. HRMS (ESI): m/z calcd for 
C31H39NO7Si + Na
+ [M + Na]+: 588.2388; found: 588.2402. 
Trans isomer 66b isolated as a white resin; yield 21%. IR (NaCl): ν̃ = 1729 cm-1 (s; ν(C=O)). 
1H NMR (CDCl3): δ 0.02 (6H, s), 1.02 (9H, s), 3.75 (3H, s), 3.77 (6H, s), 3.92 (3H, s), 4.89 
(1H, d, J=1.5 Hz), 5.10 (1H, d, J=1.5 Hz), 6.58-6.87 (10H, m). 13C NMR (CDCl3): δ -4.2, -
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4.3, 17.6, 24.1, 54.8, 54.9, 59.2, 62.3, 82.6, 95.2, 111.4, 114.2, 117.6, 119.8, 120.4, 128.2, 
131.4, 132.3, 138.3, 143.1, 149.7, 149.9, 157.3, 161.1. HRMS (ESI): m/z calcd for 
C31H39NO7Si + Na
+ [M + Na]+: 588.2388; found: 588.2402. 
Cis-(4-(3-((tert-Butyldimethylsilyl)oxy)-4-methoxy-2-nitrophenyl)-3-phenoxy-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (71) was obtained from 46 according to general method 
III.A. Amber oil; yield 61%. IR (KBr): ν̃ = 1758 cm-1 (s; ν(C=O)). 1H NMR (CDCl3): δ 0.01 
(s, 3H), 0.03 (s, 3H), 0.87 (s, 9H), 3.81 (s, 6H), 3.82 (s, 3H), 3.93 (s, 3H), 5.40 (d, J=5.7 Hz, 
1H), 5.71 (d, J=5.4 Hz, 1H), 6.68 (s, 2H), 6.90-6.96 (m, 4H), 7.22-7.28 (m, 2H), 7.82 (s, 1H). 
13C NMR (CDCl3): δ -5.3, -5.3, 17.9, 24.9, 55.6, 55.8, 60.5, 58.7, 81.7, 94.7, 108.9, 115.9, 
119.9, 122.2, 123.7, 129.0, 132.4, 134.8, 140.8, 150.3, 150.3, 153.5, 156.8, 163.2. HRMS 
(ESI): m/z calcd for C31H38N2O9Si + Na
+ [M + Na]+: 633.2239; found: 633.2232. 
Cis-4-(3-(tert-Butyldimethylsilanyloxy)-4-methoxy-5-nitrophenyl)-3-phenoxy-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (72) was obtained from 48 according to general method 
III.A. Amber oil; 73% yield. IR (NaCl): ν̃ = 1753 cm-1 (s; ν(C=O)). 1H NMR (CDCl3): δ 0.23 
(s, 6H), 0.96 (s, 9H), 3.75 (s, 6H), 3.77 (s, 3H), 3.82 (s, 3H), 5.28 (d, J=5.0 Hz, 1H), 5.51 (d, 
J=5.0 Hz, 1H), 6.20 (s(br), 1H), 6.64 (s, 2H), 6.71-6.78 (m, 3H), 7.11-7.19 (m, 3H), 7.47 (d, 
J=2.0 Hz) . 13C NMR (CDCl3): -4.8, -4.9, 17.8, 24.1, 55.8, 60.5, 62.1, 60.5, 80.4, 94.8, 115.1, 
116.1, 119.3, 122.2, 129.1, 129.3, 132.0, 141.1, 141.8, 150.4, 151.1, 153.3, 155.9, 161.9. 
HRMS (ESI): m/z calcd for C31H38N2O9Si + Na
+ [M + Na]+: 633.2239; found: 633.2245. 
Cis-4-(5-((tert-Butyldimethylsilyl)oxy)-4-methoxy-2-nitrophenyl)-3-phenoxy-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (73) was obtained from 47 according to general method 
III.A. Amber oil; yield 58%. IR (NaCl): ν̃ = 1759 cm-1 (s; ν(C=O)). 1H NMR (CDCl3): δ 0.12 
(s, 3H), 0.15 (s, 3H), 0.96 (s, 9H), 3.79 (s, 3H), 3.82 (s, 3H), 3.84 (s, 6H), 5.27 (d, J=4.7 Hz, 
1H), 5.54 (d, J=4.7 Hz, 1H), 6.70 (s, 2H), 6.84-6.96 (m, 4H), 7.12-7.25 (m, 3H). 13C NMR 
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(CDCl3): δ -4.8, -4.9, 18.0, 25.1, 55.0, 55.7, 60.5, 55.9, 80.8, 94.3, 112.1, 115.1, 115.8, 120.7, 
122.0, 129.0, 132.0, 134.5, 136.5, 144.3, 150.7, 153.2, 156.2, 162.0. HRMS (ESI): m/z calcd 
for C31H38N2O9Si + Na
+ [M + Na]+: 633.2239; found: 633.2231. 
4-[3-(tert-Butyldimethylsilanyloxy)-4-methoxyphenyl]-1-(4-methoxyphenyl)-3-
phenoxyazetidin-2-one (74) was obtained from 45 according to general method III.A. 
Colourless resin; yield 87%. IR (NaCl): ν̃ = 1743 cm-1 (s; ν(C=O)). 1H NMR (CDCl3): δ 0.05 
(s, 6H), 0.95 (s, 9H), 3.75 (s, 3H), 3.77 (s, 3H), 5.26 (d, J=5.0 Hz, 1H), 5.52 (d, J=5.0 Hz, 
1H), 6.74-6.92 (m, 12H). 13C NMR (CDCl3): δ -5.2, -5.3, 17.9, 25.2, 54.9, 54.9, 61.4, 80.6, 
111.2, 113.9, 115.1, 118.6, 120.5, 121.4, 121.6, 124.4, 128.8, 130.0, 144.4, 150.9, 155.9, 
156.5, 161.9. HRMS (ESI): m/z calcd for C29H35NO5Si + Na
+ [M + Na]+: 528.2177; found: 
528.2193. 
Cis-Ethyl-3-(4-(1-(3,4,5-trimethoxyphenyl)-4-oxo-3-phenoxyazetidin-2-yl)phenyl) 
acrylate (75). β-Lactam 268 (1.5 mmol), triethylamine (7.5 mmol), palladium(II) acetate 
(0.24 mmol), 1,3-(diphenylphosphino)propane (0.22 mmol) and ethyl acrylate (2.0 mmol) 
were combined under nitrogen. Anhydrous DMF (15 mL) was added and the mixture was 
stirred for 18 hours at 100 ºC. The mixture was cooled, diluted with CH2Cl2 (200 mL), 
washed with water (100 mL×6) and dried over anhydrous Na2SO4. The solvent was removed 
in vacuo and resulting dark brown oil was purified by flash chromatography over silica gel 
(n-hexane-ethyl acetate, 3:1). Colourless solid; yield 16%; mp 139 ˚C. IR (KBr): ν̃ = 1760 
cm-1 (s; ν(C=O)), 1713 cm-1 (s; ν(C=O)). 1H NMR (CDCl3): δ 1.34 (t, J = 7.0 Hz, 3H), 3.74 
(s, 6H), 3.79 (s, 3H), 4.27 (q, J = 7.0 Hz, 2H), 5.40 (d, J = 4.5 Hz, 1H, H4), 5.61 (d, J = 5.0 
Hz, 1H), 6.42 (d, J = 16.0 Hz, 1H), 6.61 (s, 2H), 6.80-6.82 (m, 2H), 6.93-6.97 (m, 1H), 7.18 
(d, J = 7.5 Hz, 2H), 7.42-7.44 (2H, m), 7.48 (d, J = 8.0 Hz, 2H), 7.63 (d, J = 16.0 Hz, 1H). 
13C NMR (CDCl3): δ 13.9, 55.6, 60.5, 60.2, 61.5, 80.7, 94.8, 115.2, 118.5, 121.9, 127.7, 
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128.2, 128.9, 132.4, 134.4, 134.5, 134.6, 143.2, 153.2, 156.3, 162.3, 166.3. HRMS (ESI): m/z 
calcd for C29H29NO7 + Na
+ [M + Na]+: 526.1836; found: 526.1832. 
Cis-4-(4-Methanesulfinylphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 
(76). m-CPBA (0.25 mmol) in anhydrous CH2Cl2 (10 mL) was added dropwise to a stirring 
solution of -lactam 64 (0.25 mmol) in anhydrous CH2Cl2 (10 mL) under nitrogen and the 
mixture was stirred for 2 h. The reaction mixture was washed with 5% NaHCO3 aq. solution 
(50 mL) and water (50 mL), dried over Na2SO4, and solvent removed in vacuo. 
Chromatography over silica gel (eluent: 9:1, ethyl acetate: n-hexane) yielded 76 as a pale 
brown solid; yield 63%; mp 156 oC. IR (KBr): ν̃ = 1749 cm-1 (s; ν(C=O)), 1051 cm-1 (s; ν(S-
O)). 1H NMR (DMSO-d6) δ 2.65 (s, 3H), 3.60 (s, 6H), 3.66 (s, 3H), 5.84 (d, J=4.7 Hz, 1H), 
5.97 (d, J=4.7 Hz, H3), 6.62 (s, 2H), 6.82 (dd, J=2.2 Hz, 9.1 Hz, 2H), 6.91-6.94 (m, 1H), 
7.19-7.21 (m, 2H), 7.60 (d, J=8.3 Hz, 2H), 7.89 (d, J=8.3 Hz, 2H). 13C NMR (DMSO-d6): δ 
43.3, 56.2, 60.5, 60.8, 80.7, 95.6, 115.5, 122.3, 123.8, 129.4, 129.7, 132.9, 134.8, 136.5, 
146.8, 153.6, 156.5, 162.9. HRMS (ESI): m/z calcd for C25H25NO6S + Na
+ [M + Na]+: 
490.1295; found: 490.1280. 
Cis-4-(4-Methanesulfonylphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 
(77). m-CPBA (0.66 mmol) in anhydrous CH2Cl2 (10 mL) was added dropwise to a stirring 
solution of -lactam 64 (0.25 mmol) in anhydrous CH2Cl2 (10 mL) under nitrogen and the 
mixture was stirred for 30 min. The reaction mixture was washed with 5% NaHCO3 aq. 
solution (50 mL) and water (50 mL), dried over Na2SO4, and solvent removed in vacuo. 
Chromatography over silica gel (7:3; ethyl acetate:n-hexane) yielded 77 as pale brown solid; 
yield 66%; mp 160-162 oC. IR (KBr): ν̃ = 1750 cm-1 (s; ν(C=O)), 1307, 1221 cm-1 (s; ν(S-O)). 
1H NMR (CDCl3): δ 3.04 (s, 3H), 3.77 (s, 6H), 3.81 (s, 3H), 5.49 (d, 1H), 5.67 (d, 1H), 6.59 
(s, 2H), 6.81 (d, J=8.3 Hz), 6.96 (dd, J=8.2 Hz, 2.1 Hz, 1H), 7.20 (dd, J=8.1 Hz, 2 Hz, 2H), 
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7.62 (d, J=8.0 Hz, 2H), 7.92 (d, J=8.0 Hz, 2H). 13C NMR (CDCl3): δ 43.9, 57.8, 60.5, 60.9, 
80.6, 94.8, 115.0, 122.2, 127.1, 128.6, 129.0, 132.0, 134.9, 138.9, 140.5, 153.3, 155.9, 161.9. 
HRMS (ESI): m/z calcd for C25H25NO7S + Na
+ [M + Na]+: 506.1244; found: 506.1262. 
General method IV: removal of TBDMS-protecting group. 
TBAF (1M solution in hexanes) (2 mmol) was added dropwise to a solution of the β-lactam 
silyl ether (2 mmol) in anhydrous THF under nitrogen at 0 °C. The reaction was stirred at 0 
oC until complete as indicated by TLC. Ethyl acetate (75 mL) was added and the mixture was 
washed with 0.1 M HCl (100 mL). The aqueous layer was extracted with ethyl acetate (25 
mL×2). The combined organic layers were washed with water (100 mL), brine (100 mL), and 
dried over anhydrous Na2SO4. The solvent was removed in vacuo and the crude reaction 
mixture was purified by flash chromatography over silica gel (hexane:ethyl acetate gradient). 
Cis-4-(3-Hydroxy-4-methoxyphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-
one (78a) was obtained from 66a according to general method IV. White solid; yield 73%; 
mp 176-180 oC. IR (KBr): ν̃ = 1739 cm-1 (s; ν(C=O)), 3401 cm-1 (s; ν(OH)). 1H NMR 
(CDCl3): δ 3.74 (s, 6H, 2xOCH3), 3.79 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 5.29 (d, J=5.0 Hz, 
1H, H4), 5.53 (d, J=5.0 Hz, 1H, H3), 6.65 (s, 2H, H2’, H6’), 6.78-7.21 (m, 8H, ArH). 13C 
NMR (CDCl3): δ 55.4 (OCH3), 55.6 (OCH3), 60.5 (OCH3), 61.6 (C4), 80.7 (C3), 94.8 (C2’, 
C6’), 109.9 (C2’’, C6’’), 113.9 (C2’’’), 115.3 (C5’’’), 119.7 (C4’’), 121.8 (C6’’’), 125.1 (C4’), 
128.8 (C3’’, C5’’), 132.7 (C1’), 145.1 (C1’), 145.1 (C1’’’), 146.4 (C4’’’), 153.1 (C3’, C5’), 
156.6 (C1’’), 162.5 (C=O). HRMS (ESI): m/z calcd for C25H25NO7 + Na+ [M + Na]+: 
474.1523; found: 474.1529. 
Trans-4-(3-Hydroxy-4-methoxyphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-
2-one (78b) was obtained from 66b according to general method IV. White solid; yield 68%. 
IR (KBr): ν̃ = 1737 cm-1 (s; ν(C=O)), 3498 cm-1 (s; ν(OH)). 1H NMR (CDCl3): δ 3.65 (s, 3H), 
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3.70 (s, 6H), 3.88 (s, 3H), 5.10 (d, J=1.5 Hz, 1H), 5.35 (d, J=1.5 Hz, 1H), 6.70 (s, 2H), 6.92-
7.31 (m, 8H), 7.87 (s, 1H). 13C NMR (CDCl3): δ 54.9, 54.9, 59.2, 63.0, 86.5, 95.2, 111.3, 
112.9, 114.9, 118.3, 121.6, 128.2, 129.1, 132.7, 134.2, 146.8, 147.7, 153.3, 156.8, 161.6. 
HRMS (ESI): m/z calcd for C25H25NO7 + Na
+ [M + Na]+: 474.1523; found: 474.1533. 
Cis-4-(4-Hydroxyphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (79). Cis-
(4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-
2-one (68) was obtained from 41 according to general method III.A and was deprotected 
according to general method IV to yield 79. White solid; yield 40%; mp 142 oC. IR (KBr): ν̃ 
= 1741 cm-1 (s; ν(C=O)), 3287 cm-1 (s; ν(OH)). 1H NMR (CDCl3): δ 3.72 (s, 6H), 3.80 (s, 
3H), 5.27 (d, J=4.8 Hz, 1H), 5.54 (d, J=5.0 Hz, 1H), 6.66 (s, 2H), 6.73-7.18 (9H, m). 13C 
NMR (CDCl3): δ 56.1, 60.9, 62.4, 81.2, 95.3, 114.3, 115.7, 118.7, 122.3, 129.3, 133.2, 133.8, 
134.9, 146.6, 153.5, 157.1, 163.1. HRMS (ESI): m/z calcd for C24H23NO6 + Na
+ [M + Na]+: 
444.1418; found: 444.1432. 
4-(4-Hydroxy-3-methoxyphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 
(80). 4-(4-((tert-Butyldimethylsilyl)oxy)-3-methoxyphenyl)-3-phenoxy-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (67) was obtained from 43 according to general method 
III.A and was deprotected according to general method IV to yield 80. White solid; yield 
57%; mp 158 oC. IR (KBr): ν̃ = 1757 cm-1 (s; ν(C=O)), 3415 cm-1 (s; ν(OH)). Mixture of 
isomers in 2:1 trans: cis ratio. 1H NMR (CDCl3): δ 3.75 (s, 6H), 3.80 (s, 3H), 3.85 (s, 3H), 
4.64 (d, J=1.8 Hz, 0.66H), 4.87 (d, J=1.8 Hz, 0.66H), 5.40 (d, J=5.0 Hz, 0.33H), 5.60 (d, 
J=5.0 Hz, 0.33H), 6.61-7.42 (m, 10H). 13C NMR (CDCl3): δ 56.1, 56.2, 61.7, 60.9, 81.1, 
95.3, 97.9, 114.7, 114.9, 115.7, 121.5, 122.1, 122.4, 122.6, 129.3, 130.7, 132.8, 132.9, 134.8, 
153.4, 153.6, 156.8, 156.9), 157.8, 162.8, 166.3, 167.2. HRMS (ESI): m/z calcd for 
C25H25NO7 + Na
+ [M + Na]+: 474.1523; found: 474.1528. 
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4-(3,4-Dihydroxyphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (81). 4-
(3,4-bis((tert-Butyldimethylsilyl)oxy)phenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-
2-one (70) was obtained from 42 according to general method III.A and was deprotected 
according to general method IV to yield 81. Off-white solid; yield 26%; mp 180-182 oC. IR 
(KBr): ν̃ = 1749 cm-1 (s; ν(C=O)), 3426 cm-1 (s; ν(OH)). Mixture of isomers in 2:1 trans: cis 
ratio. 1H NMR (CDCl3): δ 3.67 (s, 9H), 3.71 (s, 6H), 4.88 (d, J= 2.0 Hz, 0.65H), 5.09 (d, 
J=2.0 Hz, 0.65H), 5.28 (d, J=4.9 Hz, 0.35H), 5.52 (d, J=4.9 Hz, 0.35H), 5.69 (s(br), 0.4H), 
5.88 (s(br), 0.6H), 6.53-7.24 (m, 10H). 13C NMR (CDCl3): δ 55.5, 55.6, 60.5, 63.9, 62.2, 
80.8, 94.9, 94.9, 112.1, 114.1, 114.6, 115.8, 115.4, 119.3, 120.9, 121.9, 127.3, 128.9, 129.2, 
132.4, 132.6, 134.4, 143.5, 144.3, 144.4, 152.9, 153.1, 156.4, 156.5, 162.5. HRMS (ESI): m/z 
calcd for C24H23NO7 + Na
+ [M + Na]+: 460.1367; found: 460.1367. 
Cis-4-(3-Hydroxyphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (82). Cis-
4-(3-((tert-butyldimethylsilyl)oxy)phenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-
one (69) was obtained from 44 according to general method III.A and was deprotected 
according to general method IV to yield 82. Colourless solid; yield 43%; mp 218-220 oC. IR 
(KBr): ν̃ = 1749 cm-1 (s; ν(C=O)), 3380 cm-1 (s; ν(OH)). 1H NMR (CDCl3): δ 3.59 (s, 3H), 
3.66 (s, 6H), 5.64 (d, J=4.5 Hz, 1H), 5.86 (d, J=5.0 Hz, 1H), 6.60 (s, 2H), 6.97.23 (m, 9H), 
9.41 (s, 1H). 13C NMR (CDCl3): δ 55.8, 60.1, 61.1, 80.4, 95.1, 114.6, 115.2, 115.5, 119.2, 
121.9, 129.2, 132.8, 134.3, 134.6, 153.2, 156.6, 157.1, 162.7. HRMS (ESI): m/z calcd for 
C24H23NO6 + Na
+ [M + Na]+: 444.1418; found: 444.1414. 
Cis-4-(3-Hydroxy-4-methoxyphenyl)-1-(4-methoxyphenyl)-3-phenoxyazetidin-2-one 
(83). 4-(3-((tert-Butyldimethylsilyl)oxy)-4-methoxyphenyl)-1-(4-methoxyphenyl)-3-
phenoxyazetidin-2-one (74) was obtained from 45 according to general method III.A and 
deprotected according to general method IV to yield 83. Colourless solid; yield 46%; mp 
136-138 oC. IR (KBr): ν̃ = 1743 cm-1 (s; ν(C=O)), 3379 cm-1 (s; ν(OH)). 1H NMR (CDCl3): δ 
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3.77 (s, 3H), 3.86 (s, 3H), 5.28 (d, J=5.0 Hz, 1H), 5.52 (d, J=5.0 Hz, 1H), 6.76-6.98 (m, 8H), 
7.18-7.32 (m, 4H). 13C NMR (CDCl3): δ 54.8, 54.9, 61.3, 80.6, 111.2, 113.6, 114.8, 116.3, 
120.6, 121.0, 121.5, 124.3, 129.0, 129.4, 144.1, 148.6, 155.9, 156.6, 162.0. HRMS (ESI): m/z 
calcd for C23H21NO5 + Na
+ [M + Na]+: 414.1312; found: 414.1313. 
Cis-4-(3-Hydroxy-4-methoxy-2-nitrophenyl)-3-phenoxy-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (84) was obtained from 71 according to general method 
IV. Off-white solid; yield 22%; mp 136 oC. IR (KBr): ν̃ = 1748cm-1 (s; ν(C=O)), 3274 cm-1 (s; 
ν(OH)). 1H NMR (DMSO-d6): δ 3.61 (s, 3H), 3.71 (s, 6H), 3.81 (s, 3H), 5.52 (d, J=5.1 Hz, 
1H), 5.83 (d, J=5.1 Hz, 1H), 6.64 (s, 2H), 6.82-6.91 (m, 4H), 7.14-7.26 (m, 3H). 13C NMR 
(DMSO-d6): δ 55.8, 55.9, 60.1, 56.2, 80.8, 94.7, 113.1, 115.5, 118.6, 122.2, 129.5, 132.4, 
134.4, 136.4, 138.7, 140.9, 147.1, 148.8, 155.3, 162.5. HRMS (ESI): m/z calcd for 
C25H24N2O9 + Na
+ [M + Na]+: 519.1374; found: 519.1369. 
Cis-4-(3-Hydroxy-4-methoxy-5-nitrophenyl)-3-phenoxy-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (85) was obtained from 48 according to general method 
IV. Pale brown solid; yield 39%; mp 105 oC. IR (KBr): ν̃ = 1756 cm-1 (s; ν(C=O)), 3355 cm-1 
(s; ν(OH)). 1H NMR (CDCl3): δ 3.77 (s, 9H), 3.79 (s, 3H), 4.02 (s, 3H), 5.36 (d, J=5.0 Hz, 
1H), 5.61 (d, J=5.0 Hz, 1H), 6.26 (s(br), 1H) 6.61 (s, 2H), 6.82-6.99 (m, 3H), 7.20-7.30 (m, 
3H), 7.50 (d, J=2.1 Hz, 1H). 13C NMR (CDCl3): 55.8, 60.5, 62.1, 60.5, 80.4, 94.8, 115.1, 
116.1, 119.3, 122.2, 129.1, 129.3, 132.0, 141.1, 141.8, 150.4, 151.1, 153.3, 155.9, 161.9. 
HRMS (ESI): m/z calcd for C25H24N2O9 + Na
+ [M + Na]+: 519.1374; found: 519.1387. 
Cis-4-(5-Hydroxy-4-methoxy-2-nitrophenyl)-3-phenoxy-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (86) was obtained from 73 according to general method 
IV. White solid; yield 23%; mp 188 oC. IR (KBr): ν̃ = 1757 cm-1 (s; ν(C=O)), 3355 cm-1 (s; 
ν(OH)). 1H NMR (DMSO-d6): δ 3.65 (s, 3H), 3.72 (s, 6H), 3.89 (s, 3H), 6.02 (d, J=5.3 Hz, 
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1H), 6.27 (d, J=5.3 Hz, 1H), 6.79 (s, 2H), 6.84-7.01 (m, 4H), 7.26 (d, J=7.7, 2H), 7.80 (s, 
1H). 13C NMR (DMSO-d6): δ 56.0, 56.1, 60.2, 59.4, 81.8, 95.3, 109.3, 114.1, 116.0, 122.3, 
125.7, 129.5, 133.1, 134.5, 139.1, 146.9, 152.4, 153.4, 157.2, 164.1. HRMS (ESI): m/z calcd 
for C25H24N2O9 + Na
+ [M + Na]+: 519.1374; found: 519.1388. 
General method V. Reduction of nitro aryl azetidin-2-ones 
Acetic acid (15 mL) was added to -lactam (0.25 mmol) and zinc powder 10 μm (2.5 mmol) 
at rt under nitrogen and stirred for 7 days. The reaction mixture was filtered through celite, 
the solvent was removed from the filtrate in vacuo and the resulting residue was purified 
through by flash column chromatography over silica gel (eluent: dichloromethane). 
Cis-4-(2-Amino-3-hydroxy-4-methoxyphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl) 
azetidin-2-one (87) was obtained from 84 according to general method V. Brown solid; yield 
88%; mp 188 oC. IR (KBr): ν̃ = 1756 cm-1 (s; ν(C=O)), 3359 cm-1 (s; ν(OH)). 1H NMR 
(CDCl3): δ 2.56 (br s, 2H), 3.74 (s, 9H), 3.78 (s, 3H), 4.91 (s, 3H), 5.24 (d, J=5.0 Hz, 1H), 
5.54 (d, J=5.0 Hz, 1H), 6.59 (s, 2H), 6.79-6.84 (m, 3H), 7.19-7.28 (m, 4H). 13C NMR 
(CDCl3): δ 55.5, 55.8, 59.1, 56.2, 80.1, 94.8, 113.2, 115.3, 118.2, 121.4, 129.3, 131.2, 120.9, 
128.8, 138.0, 138.2, 147.2, 149.0, 156.3, 163.0. HRMS (ESI): m/z calcd for C25H26N2O7 + 
Na+ [M + Na]+: 489.1632; found: 489.1646. 
Cis-4-(3-Amino-5-hydroxy-4-methoxyphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl) 
azetidin-2-one (88) was obtained from 85 according to general method V. Brown solid; yield 
91%; mp: 182 oC. IR (KBr): ν̃ = 1752 cm-1 (s; ν(C=O)), 3468 cm-1 (s; ν(OH)). 1H NMR 
(CDCl3): δ 2.77 (s(br), 2H), 3.74 (s, 6H), 3.76 (s, 3H), 3.80 (s, 3H), 5.17 (d, J=5.3 Hz, 1H), 
5.52 (d, J=5.3 Hz, 1H), 6.39 (d, J=2 Hz, 1H), 6.43 (d, J=2 Hz, 1H), 6.66 (s, 2H), 6.86-7.21 
(m, 5H). 13C NMR (CDCl3): δ 55.3, 58.5, 59.9, 60.2, 80.0, 94.9, 106.9, 107.6, 114.9, 118.9, 
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127.3, 128.2, 128.5, 129.5, 131.3, 137.3, 151.0, 154.1, 154.3, 161.5. HRMS (ESI): m/z calcd 
for C25H26N2O7 + Na
+ [M + Na]+: 489.1632; found: 489.1622. 
Cis-4-(2-Amino-5-hydroxy-4-methoxyphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl) 
azetidin-2-one (89) was obtained from 86 according to general method V. Brown solid; yield 
73%; mp 210 oC. IR (KBr): ν̃ = 1756 cm-1 (s; ν(C=O)), 3447 cm-1 (s; ν(OH)). 1H NMR 
(CDCl3): δ 3.71 (s, 3H), 3.74 (s, 6H), 3.81 (s, 3H), 5.21 (d, J=4.9 Hz, 1H), 5.57 (d, J=4.9 Hz, 
1H), 5.63 (s, 1H), 6.61 (s, 2H), 6.72-6.81 (m, 4H), 7.21-7.27 (m, 2H). 13C NMR (CDCl3): δ 
56.0, 56.1, 60.0, 58.8, 80.2, 95.4, 99.5, 113.8, 117.2, 122.2, 125.2, 125.9, 128.9, 136.3, 137.2, 
141.4, 146.1, 151.3, 157.6, 164.9. HRMS (ESI): m/z calcd for C25H26N2O7 + Na
+ [M + Na]+: 
489.1632; found: 489.1646. 
Cis-4-(3-Amino-4-methoxyphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 
(90a) was obtained from 61a according to general method V. Pale brown solid; yield 83%; 
mp 158 oC. IR (KBr): ν̃ = 1754 cm-1 (s; ν(C=O)), 3368 cm-1 (s; ν(NH2)). 1H NMR (CDCl3): δ 
3.74 (s, 6H), 3.78 (s, 3H), 3.81 (s, 3H), 5.23 (d, J=5.1 Hz, 1H), 5.49 (d, J=4.4 Hz, 1H), 6.65- 
δ6.98 (m, 8H), 7.22-7.27 (m, 2H). 13C NMR (CDCl3): δ 54.9, 55.6, 60.5, 61.9, 80.8, 94.9, 
109.4, 113.7, 115.5, 118.3, 121.7, 124.5, 128.8, 132.8, 134.5, 135.8, 147.2, 153.0, 156.8, 
162.7. HRMS (ESI): m/z calcd for C25H26N2O6 + Na
+ [M + Na]+: 473.1683; found: 473.1685. 
Trans-4-(3-Amino-4-methoxyphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-
one (90b) was obtained from 61b according to general method V. Pale brown solid; yield 
94%; mp 128-130 oC. IR (KBr): ν̃ = 1756 cm-1 (s; ν(C=O)), 3465 cm-1 (s; ν(NH2)). 1H NMR 
(CDCl3): δ 3.73 (s, 6H), 3.78, (s, 3H), 3.90 (s, 3H), 3.93 (s(br), 2H), 4.85 (d, J=1.5 Hz, 1H), 
5.12 (d, J=1.5 Hz, 1H), 6.62 (s, 2H), 6.71- 6.81 (m, 5H), 7.08 (dd, J=2.1 Hz, 8.2 Hz, 1H), 
7.24-7.29 (m, 2H). 13C NMR (CDCl3): δ 55.1, 55.6, 60.5, 63.9, 86.6, 94.8, 110.1, 111.3, 
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114.9, 116.5, 121.7, 127.5, 129.2, 132.9, 134.3, 136.7, 147.4, 152.9, 156.6, 162.2. HRMS 
(ESI): m/z calcd for C25H26N2O6 + Na
+ [M + Na]+: 473.1683; found: 473.1681. 
Cis-4-(3-Aminophenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (91) was 
obtained from 62 according to general method V. Brown solid; yield 87%; mp 184 oC. IR 
(KBr): ν̃ = 1752 cm-1 (s; ν(C=O)), 3453 cm-1 (s; ν(NH2)). 1H NMR (CDCl3): δ 3.74 (s, 9H), 
3.80 (s, 3H), 5.32 (d, J=5.0 Hz, 1H), 5.58 (d, J=5.0 Hz, 1H), 6.64 (s, 2H), 6.82-7.23 (m, 9H). 
13C NMR (CDCl3): δ 55.3, 56.1, 60.9, 62.3, 81.1, 95.3, 113.7, 114.4, 115.7, 120.6, 122.3, 
129.3, 129.5, 133.1, 134.3, 134.9, 153.5, 156.9, 159.6, 162.9. HRMS (ESI): m/z calcd for 
C24H24N2O5 + Na
+ [M + Na]+: 443.1577; found: 443.1597.  
Cis-4-(4-Aminophenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (92) was 
obtained from 63 according to general method V. Brown solid, yield 79%; mp 172 oC. IR 
(KBr): ν̃ = 1753 cm-1 (s; ν(C=O)), 3362 cm-1 (s; ν(NH2)). 1H NMR (CDCl3): 1.7 (s(br), 2H), 
3.75 (s, 3H), 3.79 (s, 3H), 5.28 (d, J=5.0 Hz, 1H), 5.52 (d, J=5.0 Hz, 1H), 6.61 (s, 2H) 7.07-
7.21 (m, 9H). 13C NMR (CDCl3): δ 55.3, 56.0, 60.8, 61.1, 81.8, 94.3, 112.7, 114.9, 123.5, 
124.3, 119.4, 129.5, 133.8, 134.9, 153.5, 157.3, 160.0, 164.0. HRMS (ESI): m/z calcd for 
C24H24N2O5 + Na
+ [M + Na]+: 443.1577; found: 443.1576. 
Cis-4-(3-Hydroxy-4-methoxyphenyl)-3-(3,4,5-trimethoxyphenoxy)-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (95). (3,4,5-Trimethoxyphenoxy)acetic acid (93). To a 
stirring solution of the 3,4,5-trimethoxyphenol (25 mmol) and chloroacetic acid (25 mmol) in 
dry DMF at 0 oC under nitrogen was added 60% NaH (55 mmol) in 6 equal portions. The 
reaction was stirred at rt for 2 days, after which the solvent was removed and water was 
added (50 mL). The aqueous layer was washed with diethyl ether (60 mL), acidified to pH 1 
with conc. HCl and extracted with diethyl ether (50 mL×4). The organic extracts were dried 
over Na2SO4 and solvent removed in vacuo to yield a brown solid; yield 48%.
52 IR (KBr): ν̃ = 
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1758 cm-1 (s; ν(C=O)), 3522 cm-1 (s; ν(OH)). 1H NMR (CDCl3): δ 3.79 (s, 3H), 3.87 (s, 6H), 
4.66 (s, 2H), 6.19 (s, 2H), 7.28 (s(br), 1H). 13C NMR (CDCl3): δ 55.7, 60.6, 64.8, 77.0, 92.1, 
132.5, 153.3, 153.7, 173.0. HRMS (ESI): m/z calcd for C11H14O6 + H
+ [M + H]+: 243.0863; 
found: 243.0873. 
A solution of 93 (1 mmol) and triphosgene (0.5 mmol) in dry CH2Cl2 (10 mL) was heated at 
reflux under N2. After 30 min, triethylamine (1.5 mmol) was added, followed by the addition 
of 40 (0.5 mmol) dissolved in dry CH2Cl2 (15 mL) dropwise over 30 min. The reaction was 
refluxed for a further 6 h, cooled to rt, washed with H2O (20 mL), saturated NaHCO3 (20 
mL×2), and brine (10 mL), before being dried over MgSO4, filtered, and solvent removed in 
vacuo. 4-(3-((tert-Butyldimethylsilyl)oxy)-4-methoxyphenyl)-3-(3,4,5-trimethoxyphenoxy)-
1-(3,4,5-trimethoxyphenyl)azetidin-2-one 94 was isolated by flash chromatography over 
silica gel (eluent: 1:1, n-hexane-ethyl acetate) and was deprotected according to general 
method IV to yield 95. Colourless solid; yield 36%; mp 134-136 oC. IR (KBr): ν̃ = 1745 cm-1 
(s; ν(C=O)), 3431 cm-1 (s; ν(OH)). 1H NMR (CDCl3): δ 3.71-3.91 (m, 21H), 5.28 (d, J=5.5 
Hz, 1H), 5.56 (d, J=5.5 Hz, 1H), 5.77 (s, 2H) 6.01 (s, 2H), 6.32-6.39 (m, 3H). 13C NMR 
(CDCl3): δ 55.7, 56.0, 60.5, 60.7, 61.9, 64.8, 61.4, 81.5, 92.3, 97.5, 113.3, 114.6, 119.9, 
122.3, 127.4, 129.9, 133.9, 139.8, 141.6, 146.4, 152.6, 158.5, 168.9. HRMS (ESI): m/z calcd 
for C28H31NO10 + Na
+ [M + Na]+: 564.1840; found: 564.1859. 
2-Methoxy-5-[3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-yl]phenol (96). DIBAL-H 
(1M soln., 1.0 mmol) was added to a solution of -lactam 78a (0.25 mmol) in anhydrous 
THF (3 mL) under nitrogen. The reaction mixture was refluxed for 2 h, cooled to rt, and 
partitioned between CH2Cl2 (20 mL) and water (20 mL). The aqueous layer was further 
extracted with CH2Cl2 (10 mL), the combined organic layers were dried over Na2SO4 and 
solvent removed in vacuo. The residue was purified by flash chromatography over silica gel 
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(eluent: 1:1, ethyl acetate:n-hexane) to afford 96 as a brown oil. Yield 27%. IR (NaCl): ν̃ = 
1598 (C=O), 3412 cm-1 (s; ν(OH)). 1H NMR (CDCl3): δ 3.52 (m, 2H), 3.72 (s, 6H), 3.78 (s, 
3H), 3.83 (s, 3H), 4.79 (d, J=5.4 Hz, 1H), 5.29 (m, 1H), 6.02 (s, 2H), 6.88-6.98 (m, 6H), 
7.22-7.27 (m, 1H). 13C NMR (CDCl3): δ 53.1, 55.3, 56.1, 61.2, 69.5, 76.4, 98.7, 113.8, 115.2, 
116.3, 119.9, 120.9, 125.1, 129.1, 131.3, 141.3, 142.4, 143.6, 150.6, 156.8. HRMS (ESI): m/z 
calcd for C25H27NO6 + Na
+ [M + Na]+: 460.1731; found: 460.1721. 
4-(3-Hydroxy-4-methoxyphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidine-2-
thione (97). A solution of β-lactam 78a (0.25 mmol) and Lawesson’s reagent (2,4-bis(4-
methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-dithione) (0.275 mmol) in dry toluene (3 
mL) under nitrogen was refluxed for 12 h and stirred at rt overnight. The solvent was 
removed from the flask using a stream of nitrogen and gentle heating. The resulting solid was 
purified by flash chromatography over silica gel (elutent: 1:1, n-hexane:ethyl acetate). The 
product was washed with n-hexane to remove traces of odour from Lawesson’s reagent and 
97 was obtained as a pale yellow solid. Yield 63%; mp 110 oC. IR (KBr): ν̃ = 3336 cm-1 (s; 
ν(OH)); 1592 cm-1 (s; ν(C=S)). 1H NMR (CDCl3): δ 3.76 (s, 6H), 3.81 (s, 3H), 3.86 (s, 3H), 
5.32 (d, J=4.0 Hz, 1H), 5.61 (s(br), 1H), 5.78 (d, J=4.0 Hz, 1H), 6.77 (s, 2), 6.91-7.28 (m, 
8H). 13C NMR (CDCl3): δ 53.2, 54.6, 59.9, 69.8, 97.5, 99.7, 111.7, 114.9, 115.7, 119.7, 
121.0, 128.4, 131.2, 133.4, 137.7, 141.3, 146.8, 149.7, 157.8, 198.9. HRMS (ESI): m/z calcd 
for C25H25NO6S + Na
+ [M + Na]+: 490.1300; found: 490.1293. 
Cis-4-{4-[Bis-(2-chloroethyl)amino]phenyl}butyric acid 2-methoxy-4-[4-oxo-3-phenoxy-
1-(3,4,5-trimethoxyphenyl)azetidin-2-yl]phenyl ester (98). Chlorambucil (0.5 mmol), 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) (0.7 mmol) and DMAP (0.07 mmol) 
were dissolved in dry CH2Cl2 (35 mL) under nitrogen and stirred at rt for 10 min. -Lactam 
78a (0.5 mmol) in dry CH2Cl2 (6 mL) was added dropwise under nitrogen and the reaction 
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stirred under nitrogen overnight. The reaction mixture was diluted with CH2Cl2 (50 mL), 
washed with water (100 mL), saturated NaHCO3 aq. solution (100 mL) and water (100 mL), 
dried over Na2SO4, and the solvent removed in vacuo. Chromatography of the residue over 
silica gel (eluent: 1:1, ethyl acetate: hexane) yielded 98 as an amber oil; yield 53%. IR 
(NaCl): ν̃ = 1270 cm-1 (s; ν(CO)), 1760 (C=O) cm-1. 1H NMR (CDCl3): δ 2.00-2.07 (qt, J=7.5 
Hz, 2H), 2.58 (t, J=7.7 Hz, 2H), 2.66 (t, J=7.7 Hz, 2H), 3.63-3.67 (m, 4H), 3.71-3.76 (m, 
10H), 3.80 (s, 3H), 3.82 (s, 3H), 5.32 (d, J=5.7 Hz, 1H), 5.57 (d, J=5.4 Hz, 1H), 6.64-7.28 
(m, 14H). 13C NMR (CDCl3): δ 26.4, 32.8, 33.3, 40.1, 53.0, 53.1, 55.4, 55.7, 60.5, 61.3, 80.7, 
94.8, 111.7, 115.4, 121.9, 122.6, 124.6, 126.1, 128.9, 129.3, 129.3, 130.0, 132.6, 134.5, 
139.3, 143.9, 151.1, 153.1, 156.5, 162.5, 170.8. HRMS (ESI): m/z calcd for C39H42N2O8Cl2 + 
Na+ [M + Na]+: 759.2210; found: 759.2203. 
Cis-4-{4-[Bis-(2-chloroethyl)amino]phenyl}-N-{2-methoxy-5-[4-oxo-3-phenoxy-1-(3,4,5-
trimethoxyphenyl)azetidin-2-yl]phenyl}butyramide (99). Following procedure for 
synthesis of 98 (above), a solution of 90a (0.5 mmol) in dry CH2Cl2 (6 mL) was added to a 
solution of chlorambucil (0.5 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDCI) (0.7 mmol) and DMAP (0.07 mmol) dissolved in dry CH2Cl2 (35 mL). The product 
was obtained as an amber oil; yield 38%. IR (NaCl): ν̃ = 1686 cm-1 (s; ν(C=O)), 1755 (s; 
ν(C=O)) cm-1. 1H NMR (CDCl3) δ 2.04 (q, J=6.3 Hz, 13.7 Hz, 2H), 2.41 (dd, J=7.5 Hz, 15.2 
Hz, 2H), 2.64 (t, J=7.6, 14.8 Hz, 2H), 3.63-3.77 (m, 10H), 3.79 (s, 3H), 3.88 (s, 3H), 5.38 (d, 
J=4.9 Hz, 1H), 5.54 (d, J=4.5 Hz, 1H), 6.66-6.85 (m, 8H), 7.11-7.20 (m, 5H), 7.72 (s, 1H), 
8.59 (s, 1H). 13C NMR (CDCl3): δ 26.6, 33.5, 36.6, 40.0, 53.1, 53.1, 55.3, 55.7, 60.5, 61.73 
(C4), 80.8, 94.8, 109.5, 111.7, 115.4, 119.8, 121.7, 127.0, 128.9, 129.3, 130.0, 132.5, 132.66, 
134.4, 143.9, 144.1, 147.2, 151.2, 153.8, 156.8, 162.6, 170.5. HRMS (ESI): m/z calcd for 
C39H43N3O7Cl2 + Na
+ [M + Na]+: 758.2370; found: 758.2350. 
General method VI: Preparation of Dibenzyl Phosphate Esters 
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Carbon tetrachloride (85 mmol) was added to a solution of the appropriate phenolic β-lactam 
(17 mmol) in acetonitrile (100 mL) at 0 ºC. The resulting solution was stirred for 10 min prior 
to addition of diisopropylethylamine (35 mmol) and DMAP (1.7 mmol), followed by 
dropwise addition of dibenzyl phosphite (24.5 mmol). Upon completion as indicated by TLC, 
KH2PO4 (0.5 M, aq.) was added and the mixture was allowed to warm to rt. Combined ethyl 
acetate extracts (3×50 mL) were washed with brine (100 mL, aq.), water (100 mL) and dried 
using anhydrous Na2SO4. The solvent was reduced in vacuo and the product was isolated by 
flash column chromatography over silica gel (eluent: n-hexane: ethyl acetate gradient). 
Cis-(2-Methoxy-5-(4-oxo-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-yl)phenyl) 
dibenzyl phosphate (104a) was prepared from 78a according to general method VI. Brown 
oil; yield 86%. IR (NaCl): ν̃ = 1755 cm-1 (s; ν(C=O)), 1298 cm-1 (s; ν(P=O)). 1H NMR 
(CDCl3): δ 3.73 (s, 6H), 3.74 (s, 3H), 3.77 (s, 3H), 5.04-5.12 (m, 4H), 5.27 (d, J = 5.0 Hz, 
1H), 5.52 (d, J = 4.5 Hz, 1H), 6.61 (s, 2H), 6.83-7.33 (m, 18H). 13C NMR (CDCl3): δ 55.3, 
55.7, 60.3, 61.3, 69.5, 69.6, 80.3, 112.9, 115.6, 120.9, 121.4, 124.4, 123.7, 127.4, 128.8, 
128.9, 132.4, 134.3, 136.8, 137.7, 137.3, 147.5, 153.9, 155.9, 162.8. HRMS (ESI): m/z calcd 
for C39H38NO10P + Na
+ [M + Na]+: 734.2126; found: 734.2152. 
Trans-(2-Methoxy-5-(4-oxo-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-yl)phenyl) 
dibenzyl phosphate (104b) was prepared from 78b according to general method VI. Yellow 
oil; yield 9%. IR (NaCl): ν̃ = 1758 cm-1 (s; ν(C=O)), 1298 cm-1 (s; ν(P=O)). 1H NMR 
(CDCl3): δ 3.74 (s, 6H), 3.79 (s, 3H), 3.95 (s, 3H), 4.90 (s(br), 1H), 5.02-5.04 (m, 4H), 5.13 
(s(br), 1H), 6.60 (s, 2H), 6.88-7.34 (m, 18H). HRMS (ESI): m/z calcd for C39H38NO10P + Na
+ 
[M + Na]+: 734.2126; found: 734.2122. 
 
General Method VII: Deprotection of Dibenzyl Phosphate Esters 
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The dibenzyphosphate ester protected compound (2 mmol) was dissolved in ethanol: ethyl 
acetate (50 mL; 1:1 mixture) and hydrogenated over 10% palladium on carbon (1.2g) until 
reaction was complete on TLC (typically less than 3 h). The catalyst was removed by 
filtrataion through Celite, the solvent was reduced in vacuo and the product was isolated by 
flash column chromatography over silica gel (eluent: n-hexane: ethyl acetate gradient). 
Cis-2-Methoxy-5-(1-(3,4,5-trimethoxyphenyl)-4-oxo-3-phenoxyazetidin-2-yl)phenyl 
dihydrogen phosphate (105a) was prepared from 104a according to general method VII. 
Colourless solid, yield 21%, mp 189-190 ˚C. IR (KBr): ν̃ = 3478 cm-1 (s; ν(OH)), 1755 cm-1 
(s; ν(C=O)), 1312 cm-1 (s; ν(P=O)). 1H NMR (CDCl3): δ 3.48 (s, 3H), 3.64 (s, 6H), 3.69 (s, 
3H), 5.26 (d, J = 4.0 Hz, 1H), 5.44 (d, J = 4.0 Hz, 1H), 6.56 (s, 2H), 6.65-7.12 (m, 8H); 13C 
NMR (CDCl3): δ 55.2, 55.6, 60.4, 61.1, 80.3, 94.9, 112.0, 115.1, 121.1, 121.8, 124.7, 128.9, 
132.4, 133.6, 133.9, 134.3, 149.9, 152.9, 156.3, 162.8. HRMS (ESI): m/z calcd for 
C25H26NO10P + Na
+ [M + Na]+: 554.1187; found: 554.1171. 
Trans-2-Methoxy-5-(1-(3,4,5-trimethoxyphenyl)-4-oxo-3-phenoxyazetidin-2-yl)phenyl 
dihydrogen phosphate (105b) was prepared from 104b according to general method VII. 
Yellow oil; yield 47%. IR (NaCl): ν̃ = 3425 cm-1 (s; ν(OH)), 1756 cm-1 (s; ν(C=O)), 1300 cm-
1 (s; ν(P=O)). 1H NMR (CDCl3): δ 3.73 (s, 3H), 3.79 (s, 6H), 3.81 (s, 3H), 4.90 (br s, 1H), 
5.12 (br s, 1), 6.59 (s, 2H), 6.73-7.02 (m, 8H). HRMS (ESI): m/z calcd for C25H26NO10P + 
Na+ [M + Na]+: 554.1187; found: 554.1160. 
 
General Method VIII: Preparation of Fmoc-protected azetidin-2-ones 
DCC (5.7 mmol), Fmoc-protected amino acid (5.6 mmol) and HOBt.H2O (7.3 mmol) were 
added to a stirred solution of amino β-lactam (4.76 mmol) in anhydrous DMF (30 mL) at rt. 
After 24 h, ethyl acetate (50 mL) was added and the mixture was filtered. DMF was removed 
by washing with water (5×50 mL). The organic layer containing the product was reduced in 
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vacuo, and the product was isolated by flash column chromatography over silica gel (eluent: 
dichloromethane: methanol gradient). 
Cis-(1-((2-Methoxy-5-(4-oxo-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-yl) 
phenyl)amino)-1-oxopropan-2-yl) carbamaic acid 9H-fluoren-9-ylmethyl ester (100a) 
was prepared from 90a and and Fmoc-protected alanine according to general method VIII. 
Yellow solid; yield 22%; mp 186-187 ˚C. IR (KBr): ν̃ = 3331 cm-1 (s; ν(NH)), 1757 cm-1 (s; 
ν(C=O)), 1696 cm-1 (s; ν(C=O)). 1H NMR (CDCl3): δ 1.50 (d, J = 6.5 Hz, 3H), 3.76 (s, 6H), 
3.78 (s, 3H), 3.80 (s, 3H), 4.25 (t, J = 7.0 Hz, 1H), 4.42-4.48 (m, 3H), 5.37 (d, J = 5.0 Hz, 
1H), 5.54 (d, J = 3.5 Hz, 1H), 6.67 (s, 2H), 6.82-7.79 (m, 16H), 8.26 (br s, 1H), 8.50 (s, 1H). 
13C NMR (CDCl3): δ 13.9, 46.6, 49.1, 55.3, 55.7, 60.5, 61.6, 66.7, 80.7, 94.9, 109.6, 115.3, 
119.6, 121.7, 123.1, 123.3, 124.5, 126.6, 127.3, 128.9, 132.6, 134.4, 140.9, 143.2, 147.6, 
153.1, 156.6, 157.5, 162.6, 169.8. HRMS (ESI): m/z calcd for C43H41N3O9 + Na
+ [M + Na]+: 
766.2735; found: 766.2746. 
Trans-(1-((2-Methoxy-5-(4-oxo-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-yl) 
phenyl)amino)-1-oxopropan-2-yl)carbamaic acid 9H-fluoren-9-ylmethyl ester (100b) 
was prepared from 90b and and Fmoc-protected alanine according to general method VIII. 
Yellow oil; yield 79%. IR (NaCl): ν̃ = 3324 cm-1 (s; ν(NH)), 1759 cm-1 (s; ν(C=O)), 1597 cm-
1 (s; ν(C=O)). 1H NMR (CDCl3): δ 1.52 (d, J = 6.5 Hz, 3H), 3.78 (s, 6H), 3.83 (s, 3H), 3.87 
(s, 3H), 4.25 (t, J = 6.5 Hz, 1H), 4.46 (m, 3H), 4.97 (s(br), 1H), 5.37 (s(br), 1H), 6.67 (s, 2H), 
6.91-7.79 (m, 16H), 8.36 (s(br), 1H), 8.53 (s, 1H). HRMS (ESI): m/z calcd for C43H41N3O9 + 
Na+ [M + Na]+: 766.2735; found: 766.2762. 
Cis-(2-((2-Methoxy-5-(4-oxo-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-yl) 
phenyl)amino)-2-oxoethyl) carbamic acid 9H-fluoren-9-ylmethyl ester (101) was 
prepared from 90a and and Fmoc-protected glycine according to general method VIII. 
Colourless solid; yield 61%; mp 200-201˚C. IR (KBr): ν̃ = 3331 cm-1 (s; ν(NH)), 1755 cm-1 
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(s; ν(C=O)), 1623 cm-1 (s; ν(C=O)). 1H NMR (CDCl3): δ 3.76 (s, 6H), 3.79 (s, 3H), 3.79 (s, 
3H), 4.05-4.07 (m, 2H), 4.27 (t, J = 7.0 Hz, 1H), 4.47-4.49 (m, 2H), 5.37 (d, J = 4.5 Hz, 1H), 
5.54 (d, J = 4.5 Hz, 1H), 6.66 (s, 2H), 6.82-7.80 (m, 16H), 8.20 (s(br), 1H), 8.51 (s, 1H). 13C 
NMR (CDCl3): δ 45.0, 46.6, 55.3, 55.7, 60.5, 61.6, 66.9, 80.7, 94.8, 109.7, 115.3, 119.6, 
119.7, 121.8, 124.5, 124.6, 126.6, 127.4, 128.9, 130.4, 132.6, 134.2, 140.9, 143.2, 152.6, 
153.1, 156.8, 157.3, 162.6, 165.2. HRMS (ESI): m/z calcd for C42H39N3O9 + Na
+ [M + Na]+: 
752.2579; found: 752.2583. 
 
General Method IX: Removal of Fmoc-protecting group 
To the Fmoc-protected -lactam dissolved in CH2Cl2 (minimum volume) was added 1-
octanethiol (10 equiv.) and TBAF (2 equiv). The mixture was stirred at rt until reaction was 
complete on TLC, typically within 10 min. The solvent was reduced in vacuo and the product 
was isolated by flash column chromatography over silica gel (eluent: dichlormethane: 
methanol gradient) to afford the product. 
Cis-2-Amino-N-(2-methoxy-5-(1-(3,4,5-trimethoxyphenyl)-4-oxo-3-phenoxyazetidin-2-
yl)phenyl)propanamide (102a) was obtained from 100a according to general method IX. 
Yellow oil; yield 69%. IR (NaCl): ν̃ = 3334 cm-1 (s; ν(NH)), 1756 cm-1 (s; ν(C=O)), 1698 cm-
1 (s; ν(C=O)). 1H NMR (CDCl3): δ 1.27-1.28 (m, 3H), 3.75 (s, 6H), 3.78 (s, 3H), 3.78 (m, 
1H), 3.86 (s(br), 3H), 5.38 (d, J = 4.7 Hz, 1H), 5.53 (d, J = 4.7 Hz, 1H), 6.67 (s, 2H), 6.83-
7.21 (m, 8H). 13C NMR (CDCl3): δ 13.75, 50.1, 55.3, 55.7, 60.5, 61.7, 80.7, 94.8, 109.6, 
115.4, 119.7, 121.7, 122.7, 122.8, 128.9, 132.6, 133.6, 148.0, 153.1, 156.6, 162.7, 167.1. 
HRMS (ESI): m/z calcd for C28H31N3O7 - H
+ [M - H]+: 520.2084; found: 520.2090. 
Trans-2-Amino-N-(2-methoxy-5-(1-(3,4,5-trimethoxyphenyl)-4-oxo-3-phenoxyazetidin-
2-yl)phenyl)propanamide (102b) was obtained from 100b according to general method IX. 
Yellow oil; yield 34%. IR (NaCl): ν̃ = 3305 cm-1 (s; ν(NH)), 1724 cm-1 (s; ν(C=O)), 1687 cm-
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1 (s; ν(C=O)). 1H NMR (CDCl3): δ 1.26-1.28 (m, 3H), 3.66 (s, 6), 3.70 (s, 3H), 3.79 (s, 3H), 
3.81-3.84 (m, 1H), 5.02 (s(br), 1H), 5.12 (s(br), 1H), 6.68 (s, 2H), 6.79-6.99 (m, 8H). HRMS 
(ESI): m/z calcd for C28H31N3O7 + Na
+ [M + Na]+: 544.2054; found: 544.2043. 
Cis-2-Amino-N-(2-methoxy-5-(1-(3,4,5-trimethoxyphenyl)-4-oxo-3-phenoxyazetidin-2-
yl)phenyl)acetamide (103) was obtained from 101 according to general method IX. Yellow 
oil; yield 61%. IR (NaCl): ν̃ = 3330 cm-1 (s; ν(NH)), 1754 cm-1 (s; ν(C=O)), 1689 cm-1 (s; 
ν(C=O)). 1H NMR (CDCl3): δ 3.66 (s, 6H), 3.70 (s, 3H), 3.79 (s, 3H), 3.82-3.83 (m, 2H), 5.37 
(d, J = 5.0 Hz, 1H), 5.51 (d, J = 5.0 Hz, 1H), 6.66 (s, 2H), 6.78-7.17 (m, 8H). 13C NMR 
(100MHz, CDCl3): δ 46.7, 55.4, 55.7, 60.5, 61.3, 80.5, 94.9, 109.8, 115.3, 119.1, 121.7, 
124.7, 128.9, 132.6, 133.5, 133.9, 145.6, 153.0, 154.6, 160.4, 170.1. HRMS (ESI): m/z calcd 
for C27H29N3O7 + H
+ [M + H]+: 508.2078; found: 508.2075. 
 
Biochemical Evaluation of Activity 
Antiproliferative MTT assay. All assays were performed in triplicate for the determination 
of mean values reported. The human breast tumour cell line MCF-7 was cultured in Eagles 
minimum essential medium in a 95%O2/5% CO2 atmosphere with 10% fetal bovine serum, 2 
mM L-glutamine and 100 µg/mL penicillin/streptomycin. The medium was supplemented 
with 1% non-essential amino acids. MDA-MB-231 cells were maintained in Dulbecco’s 
Modified Eagle’s medium (DMEM), supplemented with 10% (v/v) fetal bovine serum, 2mM 
L-glutamine and 100 µg/mL penicillin/streptomycin (complete medium). Cells were seeded 
at a density of 2.5 x 104 cells/mL in a 96-well plate and incubated at 37 oC, 95% O2/5% CO2 
atmosphere for 24 h. After this time they were treated with 2 µL volumes of test compound 
which had been pre-prepared as stock solutions in ethanol to furnish the concentration range 
of study, 1 nM–100 µM, and re-incubated for a further 72 h. Control wells contained the 
equivalent volume of the vehicle ethanol (1% v/v). The culture medium was then removed 
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and the cells washed with 100 µL phosphate buffered saline (PBS) and 50 µL MTT added, to 
reach a final concentration of 1 mg/mL MTT added. Cells were incubated for 2 h in darkness 
at 37 oC. At this point solubilization was begun through the addition of 200 µL DMSO and 
the cells maintained at rt in darkness for 20 min to ensure thorough colour diffusion before 
reading the absorbance. The absorbance value of control cells (no added compound) was set 
to 100% cell viability and from this graphs of absorbance versus cell density per well were 
prepared to assess cell viability using GraphPad Prism software. 
Cytotoxicity. Cytotoxicity was determined using the CytoTox 96 non-radioactive 
cytotoxicity assay by Promega following the manufacturer’s protocol. The assay 
quantitatively measures lactate dehydrogenase (LDH) a stable cytosolic enzyme that is 
released upon cell lysis. Released LDH in culture supernatant is measured in a 30 minute 
coupled enzymatic assay, which results in the conversion of a tetrazolium salt (INT) into a 
red formazan product. MCF-7 cells were seeded in 96-well plates, incubated for 24 hours and 
then treated with compounds as described for the MTT antiproliferation assay above. After 
72 hours, 20 μL of lysis solution (10X) was added to the ‘blank’ wells and left for 1 hour to 
ensure 100% death. 50 μL was removed from each well and transferred to a new 96-well 
plate. 50 μL of substrate mix from the LDH assay kit was added and the plate was incubated 
in the dark at rt for 30 minutes. After this period, 50 μL of stop solution was added to each 
well before reading the absorbance at a wavelength of 490 nm using a Dynatech MR5000 
plate reader. Percentage cell death was calculated at 10 μM. 
Immunofluorescence Microscopy. Confocal microscopy was used to study the effects of 
drug treatment on MCF-7 cytoskeleton. For immunofluorescence, MCF-7 cells were seeded 
at 1 × 105 cells/ml on eight chamber glass slides (BD Biosciences). Cells were either 
untreated or treated with vehicle [1 % ethanol (v/v)], paclitaxel (1 μM), 2 (100 nM) or 90b 
(100 nM) for 16 h. Following treatment cells were gently washed in PBS, fixed for 20 min 
 58 
 
with 4 % paraformaldehyde in PBS and permeabilised in 0.5 % Triton X-100. Following 
washes in PBS containing 0.1 % Tween (PBST), cells were blocked in 5 % bovine serum 
albumin diluted in PBST. Cells were then incubated with mouse monoclonal anti-α-
tubulin−FITC antibody (clone DM1A) (Sigma) (1:100) for 2 hr at rt. Following washes in 
PBST, cells were incubated with Alexa Fluor 488 dye (1:450) for 1 hr at rt. Following washes 
in PBST, the cells were mounted in Ultra Cruz Mounting Media (Santa Cruz Biotechnology, 
Santa Cruz, CA) containing 4,6-diamino-2-phenolindol dihydrochloride (DAPI). Images 
were captured by Leica SP8 confocal microscopy with Leica application suite X software. All 
images in each experiment were collected on the same day using identical parameters. 
Experiments were performed on three independent occasions. 
Tubulin Polymerization. Tubulin polymerisation was carried out using an assay kit supplied 
by Cytoskeleton [Tubulin polymerization HTS assay using >97% pure porcine tubulin, OD-
based (BK004P)], based on the principal that light is scattered by microtubules to an extent 
that is proportional to the concentration of the microtubule polymer. Compounds that interact 
with tubulin alter its polymerisation, and this can be detected using a spectrophotometer. The 
absorbance at 340 nm at 37°C is monitored. The assay was performed as described in version 
2.2 of the tubulin polymerisation assay kit manual.53 
Colchicine-Binding Site Assay. MCF-7 cells were seeded at a density of 5 × 104 cells/well 
in 6-well plates and incubated overnight. Cells were treated with vehicle control [ethanol (0.1 
% v/v)], 1 or compound 90b (both 10 μM) for 2 h. After this time, selected wells were treated 
with N,N’-ethylene-bis(iodoacetamide)(EBI)(Santa Cruz Biotechnology) for 1.5 h. Following 
treatment, cells were twice-washed with ice-cold PBS and lysed by addition of Laemmli 
buffer. Samples were separated by SDS-PAGE, trasnsferred to polyvinylidene difluoride 
membranes and probed with β-tubulin antibodies (Sigma-Aldrich).42 
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Stability Studies. Analytical HPLC stability studies were performed using a Waters In-Line 
Degasser AF and a Waters 717plus Autosampler. The column used was a hypersil Gold PFP 
C8 1.9µm (150×4.6 mm) reverse phase chromatography column. Samples were detected 
using a wavelength of 254 nm. All samples were analysed using acetonitrile: water (50:50) 
over 10 min and a flow rate of 1 ml/min. Stock solutions are prepared by dissolving 10 mg of 
compound in 10 ml of mobile phase. Phosphate buffers at the desired pH values (4, 7.4, and 
9) were prepared in accordance with the British Pharmacopeia monograph 2010. 200µL of 
stock solution was diluted with 9.8 mL of appropriate phosphate buffer, shaken and injected 
immediately. Samples were withdrawn and analysed at t=0 min, and every 3 hours until 24 
hours. 
Computational Procedure. For ligand preparation, all compounds were built using 
ACD/Chemsketch v10 to generate SMILES. A single conformer from each string was 
generated using Corina v3.4 and ensuring Omega v2.2.1 was subsequently employed to 
generate a maximum of 1000 conformations of each compound. For the receptor preparation, 
PDB entry 1SA0 was downloaded from the Protein Data Bank (PDB).6 All waters were 
retained in both isoforms. Addition and optimisation of hydrogen positions for these waters 
was carried out using MOE 2011.10 ensuring all other atom positions remained fixed.54 
Using the reported X-ray structure of tubulin co-crystallised with a colchicine derivative, 
DAMA-colchicine (PDB entry – 1SA0), possible ligand binding orientations were probed 
with the docking program FREDv2.2.3 (Openeye Scientific Software). Docking was carried 
out using FREDv2.2.3 in conjunction with Chemgauss3, PLP Scoring function. 3-D ligand 
conformations were enumerated using CORINAv3.4 (Molecular Networks GMBH) for 
ligands followed by generation of multiple conformations using OMEGAv2.2.1 (Openeye 
Scientific Software). Each conformation was subsequently docked and scored with 
Chemgauss3 PLP as outlined previously. The top binding poses were refined using the LigX 
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procedure (MOE 2011.10) together with Postdock analysis (SVL script; MOE) of the docked 
ligand poses.  
X-Ray Crystallography. The data sets for all the crystal samples were collected on a Bruker 
Smart Apex Diffractometer. Suitable crystals from each sample were selected and mounted 
on a glass fiber tip and placed on the goniometer head in a 123 K N2 gas stream. Each data 
set was collected using Bruker Smart Version 5.625 software run in multirun mode and 2400 
image frames, of 0.3° per frame, were recorded. Data integration and reduction were carried 
out using Bruker* Saint+ Version 6.45 software and corrected for absorption and polarization 
effects using Sadabs Version 2.10 software. Space group determinations, structure solutions 
and refinements were obtained using Bruker Shelxtl Ver. 6.14 software. All non-hydrogen 
atoms were refined anisotropically. Hydrogen atoms (excluding water) were assigned to 
calculated positions using a riding model with appropriately fixed isotropic thermal 
parameters.  
Crystal Data for 49: C27H29NO8, M = 495.51, Triclinic, a = 8.9118(5), b = 11.7367(7), c = 
12.2126(7) Å, α = 90.8580(10)°, β = 90.4980(10)°, γ = 100.6200(10)°, U = 1255.27(13)Å3, T 
= 150 K, space group P-1, Z = 2, μ (Mo Kα) = 0.097 mm−1, ρ = 1.311Mg/cm3, 10029 
reflections collected, 4406 unique, (Rint = 0.020), R indices (all data) 
aR1 = 0.0491, wR2 [I > 
2σ(I)] = 0.1216, Gof on F2= 1.111. CCDC deposition number: 1408845. 
Crystal Data: 55a: C25H24BrNO6, M=514.36, Monoclinic, a = 11.4077(8) Å, b = 12.4910(8) 
Å, c = 16.2876(11) Å; α = 90°, β = 94.226(2)°, γ = 90°; U = 2314.6(3) Å3, T = 100(2) K, 
space group P 1 21/c 1, Z = 4, μ (Mo Kα) = 1.54178 Å, , ρ =1.476 g/cm3, 35486 reflections 
collected, independent reflections 4048 [R(int) = 0.0366], R indices (all data) R1 = 0.0289, 
wR2 = 0.0863; w=1/[σ2(Fo2)+(0.0555P)2+2.8462P] where P=(Fo2+2Fc2)/3; Gof = 0.938. aR1 = 
||Fo| − |Fc||/ |Fo|, wR2 = [ w(Fo2 − Fc2)2/ w(Fo2)2]1/2. CCDC deposition number: 1408847. 
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Crystal Data for 60: C28H25NO5, M = 455.49, Triclinic, a = 10.1226(5), b = 14.7272(7), c = 
17.3808(8)Å,= 74.9040(10)°,= 75.6960(10)°,  = 74.3650(10)°, U = 2365.1(2)Å3, T = 
150 K, space group P-1, Z = 4, μ (Mo Kα) = 0.088 mm−1, ρ = 1.279Mg/cm3, 18923 
reflections collected, 8330 unique, (Rint = 0.0242), R indices (all data) 
aR1 = 0.042, wR2 [I > 
2σ(I)] = 0.1170, Gof = 1.039, aR1 = ||Fo| − |Fc||/ |Fo|, wR2 = [ w(Fo2 − Fc2)2/
w(Fo
2)2]1/2. CCDC deposition number: 1408844.  
Crystal Data for 77: C50H50C10N2O14S2, M = 967.04, Triclinic, a = 9.5683(19), b = 
11.422(2), c = 11.892(2)Å, α = 114.97(3)°, β = 101.24(3)°, γ = 93.60(3)°, U = 1140.1(4)Å3, T 
= 150 K, space group P-1, Z = 1, μ (Mo Kα) = 0.190 mm−1, ρ = 1.408Mg/cm3, 11169 
reflections collected, 5463 unique, (Rint = 0.0203), R indices (all data) 
aR1 = 0.1275, wR2 [I > 
2σ(I)] = 0.3306, Gof = 1.110, aR1 = ||Fo| − |Fc||/ |Fo|, wR2 = [ w(Fo2 − Fc2)2/ w(Fo2)2]1/2. 
CCDC deposition number: 1408846. 
Crystal Data for 50b: C50H52N2O13, M = 888.94, Monoclinic, a = 19.4658(13), b = 
13.4807(9), c = 17.5627(12), Å, α = 90°, β = 106.5660(10)°, γ = 90°, U = 4417.4(5)Å3, T = 
150 K, space group C2/c, Z = 4, μ (Mo Kα) = 0.097 mm−1, ρ = 1.337Mg/cm3, 17189 
reflections collected, 3889 unique, (Rint = 0.0267), R indices (all data) 
aR1 = 0.0360, wR2 [I > 
2σ(I)] = 0.0987, Gof = 0.902, aR1 = ||Fo| − |Fc||/ |Fo|, wR2 = [ w(Fo2 − Fc2)2/ w(Fo2)2]1/2. 
CCDC deposition number: 1408848. 
Crystal Data for 58b: C25H22N2O5, M = 430.45, Monoclinic, a = 14.9002(9), b = 14.0903(8), 
c = 21.0318(12)Å, α = 90°, β = 94.6700(10)°, γ = 90°, U = 4400.9 (4)Å3, T = 150 K, space 
group P2(1)/c, Z = 8, μ (Mo Kα) = 0.091 mm−1, ρ = 1.299Mg/cm3, 34424 reflections 
collected, 7741 unique, (Rint = 0.0227), R indices (all data) 
aR1 = 0.0328, wR2 [I > 2σ(I)] = 
0.1216, Gof = 1.111, aR1 = ||Fo| − |Fc||/ |Fo|, wR2 = [ w(Fo2 − Fc2)2/ w(Fo2)2]1/2. CCDC 
deposition number: 1408851. 
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Crystal Data for 78b: C25H25NO7, M = 451.46, Triclinic, a = 10.1929(11), b = 10.4180(11), c 
= 12.6792(14)Å, α = 90.803(2), β = 110.232(2)°, γ = 117.556(2)°, U = 2052.6(13)Å3, T = 150 
K, space group P-1, Z = 2, μ (Mo Kα) = 0.100 mm−1, ρ = 1.369Mg/cm3, 8726 reflections 
collected, 3854 unique, (Rint = 0.0151), R indices (all data) 
aR1 = 0.0522, wR2 [I > 2σ(I)] = 
0.1385, Gof = 1.027, aR1 = ||Fo| − |Fc||/ |Fo|, wR2 = [ w(Fo2 − Fc2)2/ w(Fo2)2]1/2. CCDC 
deposition number: 1408850. 
Crystal Data for 90b: C25H26N2O6, M = 450.48, Orthorombic, a = 21.8994(19), b = 
7.6060(7), c = 28.035(2)Å, α = β = γ = 90°, U = 4669.7(7)Å3, T = 150 K, space group Pbca, Z 
= 8, μ (Mo Kα) = 0.092 mm−1, ρ = 1.282Mg/cm3, 46377 reflections collected, 4105 unique, 
(Rint = 0.0746), R indices (all data) 
aR1 = 0.0432, wR2 [I > 2σ(I)] = 0.1204, Gof = 0.999, aR1 
= ||Fo| − |Fc||/ |Fo|, wR2 = [ w(Fo2 − Fc2)2/ w(Fo2)2]1/2. CCDC deposition number: 
1408849.  
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Table 1: Antiproliferative Effects and Cytotoxicity of -Lactams 49-65, 75-92, 95-99, 102, 103 and 105 in MCF-7 Cells  
 
 
IC50 value 
(M)a 
% Cell Death 
(10 μM)b 
 R1 R2 R3 R4 R5   
49 H OCH3 OCH3 OCH3 H 29 0 
50a H H OCH3 H H 35 6.5 
50b H H OCH3 H H 6.9 7.3 
51 H OCH3 H H H 171 22 
52 H OCH3 OCH3 H H 26 11.2 
53 H -OCH2O- H H 48 8.3 
54 H H Br H H 48 nd 
55a H Br OCH3 H H 5.1 6.4 
55b H Br OCH3 H H 31 3.9 
56 H F OCH3 H H 6.3 70 
57 H H N(CH3)2 H H 31 5.9 
58a H H CN H H 31.6 4.8 
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58b H H CN H H 168 2.1 
59 H -C4H4- H H 282 10.7 
60 -C4H4- H H H 53 4.6 
61a H NO2 OCH3 H H 69 5.3 
61b H NO2 OCH3 H H 4.1 5.2 
62 H NO2 H H H 30 16.7 
63 H H NO2 H H 63 27 
64 H H SCH3 H H 7.7 8.1 
65 H H N3 H H 23 5.8 
75 H H C2H4CO2C2H5 H H 87 nd 
76 H H SOCH3 H H 20 1.7 
77 H H SO2CH3 H H 62 10.2 
78a H OH OCH3 H H 0.383 2.8 
78b H OH OCH3 H H 0.038 29 
79 H H OH H H 48 0.1 
80 H OCH3 OH H H 32 5.1 
81 H OH OH H H 4.5 6.0 
82 H OH H H H 54 22 
83 See Scheme 3 49 10.4 
84 NO2 OH OCH3 H H 89 12.7 
85 H OH OCH3 NO2 H 69 12.1 
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86 H OH OCH3 H NO2 59 9.9 
87 NH2 OH OCH3 H H 19 52 
88 H OH OCH3 NH2 H 8.8 14.0 
89 H OH OCH3 H NH2 20 70 
90a H NH2 OCH3 H H  12.2 7.7 
90b H NH2 OCH3 H H  0.013 10.2 
91 H NH2 H H H 17 48 
92 H H NH2 H H 160 14.7 
95 See Scheme 5 33 10.9 
96 See Scheme 6 3.3 19.8 
97 See Scheme 6 7.5 4.8 
98 H OChlorambucil OCH3 H H 0.41 8.0 
99 H NHChlorambucil OCH3 H H 145 3.2 
102a H NHC(O)C(CH3)NH2 OCH3 H H 9.2 nd 
102b H NHC(O)C(CH3)NH2 OCH3 H H 0.23 nd 
103 H NHC(O)CHNH2 OCH3 H H 6.5 nd 
105a H OP(O)(OH)2 OCH3 H H 42 nd 
105b H OP(O)(OH)2 OCH3 H H 23 nd 
2c 0.0039 5.5 
aIC50 values are half maximal inhibitory concentrations required to block the growth stimulation of MCF-7 cells. Values represent the mean for three 
experiments performed in triplicate. 
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bLactate Dehydrogenase assay: Following treatment of the cells, the amount of LDH was determined using LDH assay kit from Promega (G1780). 
Data is presented as % cell death at a concentration of 10 μM. 
cThe IC50 value obtained for 2 (0.0039 μM for MCF-7) is in good agreement with reported values.26, 55 
*nd = not determined. 
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Table 2. In vitro inhibition of tubulin polymerization for compounds 57, 58b, 78a, 78b, 90b 
and 2a 
Compound Fold-reduction in Vmax 
57 0 
58b 0 
78a 1.1 
78b 3.2 
90b 1.8 
2 6.0 
 
aEffect of 57, 58b, 78a, 78b, 90b and 2 (all at final concentration of 10 μM) on in vitro 
tubulin polymerisation. Purified bovine tubulin and GTP were mixed in a 96-well plate at 
37oC. Ethanol (1% v/v) was used as a vehicle control. The effect on tubulin assembly was 
monitored in a Spectramax 340PC spectrophotometer at 340 nm at 30 second intervals for 60 
minutes at 37 oC. Fold inhibition of tubulin polymerization was calculated using the Vmax 
value for each reaction. The results represent the mean for three separate experiments. 
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Figures.  
 
Figure 1. Small molecules that interact with the colchicine-binding site of tubulin 
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Figure 2. CA-4 2 and β-lactam 90b depolymerise the microtubule network of MCF-7 cells. MCF-7 cells were treated with vehicle control [1% 
ethanol (v/v)], paclitaxel (1 μM), 2 (100 nM) or 90b (100 nM) for 16 h. Cells were fixed in 4% paraformaldehyde and stained with mouse 
monoclonal anti-α-tubulin−FITC antibody (clone DM1A) (green), Alexa Fluor 488 dye and counterstained with DAPI (blue). Images were 
captured by Leica SP8 confocal microscopy with Leica application suite X software. Representative confocal micrographs of three separate 
experiments are shown. Scale bar: 30 μM (top images); 10 μM (bottom images). 
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Figure 3. Effects of 1 and β-lactam 90b on the inhibition of the bisthioalkylation of Cys239 
and Cys354 of β-tubulin by N,N’-ethylene-bis(iodoacetamide)(EBI) in MCF-7 cells. MCF-7 
cells were treated with vehicle control [ethanol 0.1% (v/v)], 1 or 90b (both 10 μM) for 2 h; 
selected samples were then treated with EBI for an additional 1.5 h. Cells were harvested, 
lysed and analysed using sedimentation and Western blotting for β-tubulin and β-tubulin-EBI 
adduct. Results are indicative of three separate experiments, performed independently.
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Figure 4. Differential effects of 78b and 90b on the cell cycle and apoptosis in MCF-7 cells. 
Cells were treated with either vehicle [0.1% ethanol (v/v)], 78b (100 nM) or 90b (50 nM) for 
24, 48 and 72 hr. Cells were then fixed, stained with PI, and analyzed by flow cytometry. Cell 
cycle analysis was performed on histograms of gated counts per DNA area (FL2-A). The 
number of cells with <2N (sub-G1), 2N (G0G1), and 4N (G2/M) DNA content was determined 
with CellQuest software. Statistical analysis was performed using Prism software. A two-way 
ANOVA was employed to determine significant differences between and vehicle controls 
and treated samples. Values represent the mean ± S.E.M. for at least two separate 
experiments.  
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Figure 5. ORTEP representations of the X-ray crystal structures of azetidinones (A) 78b and 
(B) 90b with 50% thermal ellipsoids. 
B
. 
A
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Figure 6. (Left) Docked solution of 78a (pink) and 78b (blue) with DAMA-colchicine (red)6; 
(Right) 2D representation of the ligand-protein interactions of 78b with the colchicine-
binding site, rendered using LigX module of MOE. 
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Schemes 
Scheme 1. Synthesis of benzaldehydes 8, 11, 13 and imines 14-48a 
aReagents and conditions: (a) concd HNO3, acetone, rt, 30 min, 42%, 31%; (b) (CH3CO)2O, 
KOH, diethyl ether, 0 °C, 30 min, 93%; (c) concd HNO3, -18 to -5 °C, 20 min, 82%; (d) 5% 
aq. NaOH, rt, 8%; (e) NaNO2, H2O, 2M H2SO4, 0 °C, 15 min; NaN3, H2O, rt, 1 h, 90%; (f) 
PCC, CH2Cl2, rt, 1 h, 78%; (g) EtOH, H2SO4, reflux, 5 h, 10-95%; (h) t-BuMe2SiCl, DBU, 
CH2Cl2, rt, until complete as indicated by TLC, 75-92%. R=H unless otherwise indicated. 
Scheme 2. Synthesis of azetidinones 49-77a 
aReagents and conditions: (a) C6H5OCH2COCl, Et3N, anhyd CH2Cl2, 40 °C, 5 h then rt, 16 h, 
21-98%; (b) (b) Pd(OAc)2, (C6H5)2PC3H6P(C6H5)2, Et3N, anhyd DMF, 100ºC, 18 h, 16%; (c) 
mCPBA (1 equiv.), anhyd CH2Cl2, rt, 2 h, 63%; (d) mCPBA (2.5 equiv.), anhyd CH2Cl2, rt, 
30 min, 66%. Products obtained as a mixture of enantiomers; one enantiomer represented. 
R=H unless otherwise indicated. 
Scheme 3. Synthesis of phenolic azetidinones 78-83a 
aReagents and conditions: (a) TBAF, THF, 0 °C, 15 min, 26-57%. Products obtained as a 
mixture of enantiomers; one enantiomer represented. 
Scheme 4. Synthesis of amino azetidinones 84-92a 
aReagents and conditions: (a) TBAF, THF, 0 °C, 15 min, 22-39%; (b) Zn dust, CH3CO2H, rt, 
7 days, 73-94%. Products obtained as a mixture of enantiomers; one enantiomer represented. 
R=H unless otherwise indicated. 
Scheme 5. Synthesis of azetidinone 95a 
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aReagents and conditions: (a) ClCH2CO2H, anhyd DMF, NaH, 0 °C then rt, 2 days, 48%; (b) 
Triphosgene, Et3N, anhyd CH2Cl2, reflux, 6 h; (c) TBAF, THF, 0 °C, 15 min, 22-39%, 36%. 
Product obtained as a mixture of enantiomers; one enantiomer represented. 
Scheme 6. Synthesis of azetidinones 96-99a 
aReagents and conditions: (a) DIBALH, anhyd THF, reflux, 2 h, 27%; (b) Lawesson's 
reagent, anhyd toluene, reflux, 12 h, rt, overnight, 63%; (c) Chlorambucil, DMAP, EDCI, 
anhyd CH2Cl2, rt, 24 h, 38-53%. Products obtained as a mixture of enantiomers; one 
enantiomer represented. 
Scheme 7. Synthesis of amino acid prodrugs 102a, 102b and 103a 
aReagents and conditions: (a) N-Fmoc-L-amino acid, anhyd DMF, DCC, HOBt.H2O, rt, 24h, 
22-79%; (b) TBAF, 1-octanethiol, CH2Cl2, rt, until complete as indicated by TLC, 34-69%. 
Products obtained as a mixture of enantiomers; one enantiomer represented. 
Scheme 8. Synthesis of phosphate ester prodrugs 105a and 105ba 
aReagents and conditions: (a) CCl4, CH3CN, DIPEA, DMAP, dibenzyl phosphite, 0 °C, until 
complete as indicated by TLC, 9%, 86%; (b) H2, Pd/C, EtOH:EtOAc (1:1), rt, until complete 
as indicated by TLC, 21%, 47%. Products obtained as a mixture of enantiomers; one 
enantiomer represented. 
  
 84 
 
Scheme 1 
 
  
 85 
 
Scheme 2  
 
  
 86 
 
Scheme 3 
 
  
 87 
 
Scheme 4 
 
  
 88 
 
Scheme 5 
 
  
 89 
 
Scheme 6 
 
  
 90 
 
Scheme 7 
 
  
 91 
 
Scheme 8 
 
  
 92 
 
Graphical Abstract (for Table of Contents Only) 
 
